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Chapter 1
Organic Synthesis
1. Amidines as precursors for heterocycles synthesis
Since several years in our laboratories we studied the role of amidines as precursors
of heterocyclic compounds. The key step in the synthesis of such amidines is the 1-
3 dipolar cycloaddition between an olephinic dipolarophile, usually an enamine, and
a substituted azido derivative to yield a triazoline derivative that undergoes thermal
rearrangement furnishing the corresponding amidine .
Scheme 1
Such rearrangement was observed for the first time by prof. Fusco1 in 1961 making
available a new route to amidinic synthones .
In our labs, tertiary amidines were successfully converted into several heterocyclic
compounds, including substituted quinolines2, quinoxalines3 and quinazoline4.
Furthermore substituted amidines where used in the synthesis of amino-
imidazolines and imidazoles5
As could be noticed by Scheme 2, the synthetic versatility of tertiary amidines is
strictly related to the functionalization of the azido precursor.
In a recent study we synthesized 5-amino-v-triazolines bearing at N-1 a pyranonic
ring. Thermal rearrangement of the investigated dihydro-v-triazoles gave a mixture
of nitrogen functionalized tertiary amidines and 1H-pyrano[4,3-b]pyrrol-4-ones.
Scheme 3 shows that by choosing the appropriate reaction conditions it was possible
to achieve selectively one or the other product6. 
1 R. Fusco, G. Bianchetti, D. Pocar, Gazz. Chim. Ital., 1961, 91, 933-957.
2 E. Beccalli, E. Erba, L.M. Gelmi, D. Pocar, J.C.S. Perkins1, 1996, 1206.
3 Battistini, E. Erba, Synthesis, 1992, 1206.
4 E. Erba, D. Sporchia, J.C.S. Perkins1, 1997, 3021.
5 L. Citerio, D. Pocar, R. Stradi and B. Gioia, J.C.S. Perkins1, 1978, 4, 309-314.
6 E. Erba, D. Pocar and P. Trimarco, J.C.S. Perkins1, 2001, 14, 1723-1728.
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Scheme 2
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Scheme 3
The choice of the pyrone substituent was made for mainly two reasons: it's
occurrence in many natural products and it's peculiar reactivity. Specifically, it was
our interest to explore the possibility of the triacetic lactone to react with
nucleophiles . It is known that several kind of nucleophiles can react with pyran-2-
one at C-2 and at C-6 causing initial ring opening7. However reactions resulting in
opening of the pyrone ring without transformation into a different cyclic product are
relatively uncommon, because highly functionalized open-chain compounds arising
from pyronic ring opening exhibit a strong tendency to cyclize again into new
heterocycles. Several examples of transformation of triacetic lactone into 4-
hydroxy-2-pyridones by treatment with ammonia and primary amines have been
reported. Scheme 4 shows an example in which the treatment of triacetic lactone
with an excess of primary amine results firs in a nucleophilic attach at C-2, then
enamine formation and ring condensation and finally nucleophilic substitution at
7 (a) G.P. Ellis, Comprehensive Heterocyclic Chemistry; A.J. Boulton, A. McKillop, Eds.;
Pergamon: Oxford, 1984; Vol. 3, p 681 and references cited therein.
      (b) M. Mañas, R. Pleixats, Adv. Heterocycl. Chem., 1992, 53, 59 and references cited therein.
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C4. 
Scheme 4
Diketoamide 2 and amidine 3 have been isolated, and independent conversion of 4
into 5 has also been reported, suggesting a ranking of electrophilic reactivity C-2 >
C-6 > C-4.
It has been reported that the methylene group linked to a amidine tertiary function is
easily transformed into carbanion able to react in intra molecular nucleophilic
condensations4. With the support of such theoretical preambles we decided to
exploit either pyran-2-one nucleus reactivity and nucleophilic carbon atom on C-α
to amidine group with the purpose to fine a satisfactory route to synthesize
functionalized 2-pyridinacetamides that are of general interest owing to the
presence of similar structures in several compounds with antiarrhytmic8, anti HIV
and enzymatic inhibitory activity9. Literature reports examples for the synthesis of
amides derived from 2-pyridinacetic acid. For example M. Gonschior et. al
reported the synthesis for N-[2-(2-pyridyl)ethyl]amino and N,N-bis[2-(2-
pyridyl)ethyl]amino steroids, through an amidic intermediate10 (Scheme 5):
8 C. Bernhart et al., J. Med. Chem., 1983, 26, 451-455 
9 D. R. Sliskovic et al, J. Med. Chem., 1998, 41, 682-690. 
10 M. Gonschior et. al, Tetrahedron: Asymmetry, 2000, 11, 2159-2182
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Scheme 5
Such synthetic scheme uses commercial 2-pyridinacetic acid hydrochloride, and
therefore yields only unsubstituted amides.
More versatile could be the way adopted by Zhou et. al for the synthesis of chiral
bis(oxazolinyl)bipyridine ligands11, in which the amide is obtained from directly
from the ester (Scheme 6):
Scheme 6
Although the amidation step requires 7 days of reflux in xylene, and therefore is not
so practical. For this reason we thought there was the need for new versatile
synthesis for substituted 2-pyridinacetamides. 
The first question that arose was if a pyrone ring substituted at C-5 with an amidinic
moiety could maintain the same reactivity as unsubstituted triacetic lactone toward
nucleophiles. Politzer et. al reported that ab-initio electrostatic potential calculations
could help in identifying most reactive sites toward nucleophilic attacks, by
mapping the calculated electrostatic potential on a 0.002 el/bohr3 isodensity
11 Qi-Lin Zhou et al, Tetrahedron: Asymmetry , 2002, 13, 161-165
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surface12; it has been shown, for a group of diatomic molecules and for methane,
that this contour gives physically reasonable molecular dimensions, and
encompasses at least 95% of the electronic charge. As shown in Equation 1, such
potential derives from the difference between the positive nuclear contribution (first
term) and the negative electronic contribution (second term). Equation 1 express
rigorously the electrostatic potential V(r) at any point r in the space of a molecule.
Equation 1 
ZA is the charge on nucleus A, located at RA, and ρ(r) is the electronic density
function of the molecule, which can be obtained by an ab initio self-consistent-field
(SCF) molecular orbital approach. Then, in order to answer our question, we
performed ab initio calculations at the HF/6-31G** level on both unsubstituted
triacetic lactone and 5-amidino substituted pyrone. Figure 1 represents resulted
electrostatic potential mapped on a 0.002 el/bohr3 isodensity surface; it's evident
that the positive charge (blue) on the pyronic ring for both triacetic lactone and
amidine is well localized mainly on carbons 2 and 6. However we notice a reduction
of the positive potential intensity for amidine substituted pyronic C-2, with a value
similar to that of C-6. This could result in lower selectivity between C-2 and C-6
nucleophilic attack. Must also be noted that the electrostatic potential on amidino-
pyronic C-4 tends to be negative, while on pyronic C-4 is positive; this suggest us
that nucleophilic substitution on amidino-pyronic C-4 should not happen.
Those preliminary data suggested us that the synthetic path designed to obtain 2-
pyridineacetamides should be possible. 
12 Politzer et al. J. Phys. Chem., 1991, 95, 844-848.
6
Figure 1
electrostatic potential calculations: positive potential values are distributed mainly on C-2 and C-6
of the pyranonic ring; C-2 and C-4 amidine values are lower compared with pyranonic C-2 and C-4
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2. Synthesis of 2-pyridinacetamides
We recently described the preparation of 4,5-dihydro-v-triazoles 3a-d, f, h-j from
cycloaddition of azide 1 and appropriate enamines 2 in benzene solution6 (Scheme
1).
Scheme1
Compounds 3 have trans configuration, as they show a NMR coupling constant of
about 3Hz. Compounds 3 when heated in boiling n-propanol or in toluene gave the
corresponding amidines 4. It is well known the cleavage of the N(1)-N(2) bond in
the 4,5-dihydro-v-triazole nucleus is made easier by electron–withdrawing groups
on N-113. Concerning aromatic substituted amidines, further optimization of this
reaction scheme resulted in not isolating the dihydro-v-triazoles 3 but reacting
enamines 2 with the azido derivative 1 directly in n-propanol for 2 hours at room
13 P.K.B. Kadaba, B. Stanovnik, M. Tišler, Adv. Heterocycl. Chem., 1984, 37, 339 and references
cited therein. 
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temperature and  then refluxing the reaction mixture for 2 hours (Scheme 2). 
Scheme 2
The amidino compounds, according to Scheme 2 are collected as precipitate just by
cooling the n-propanol solution. Enamines 2 has been prepared by reaction of the
corresponding benzaldehyde and morpholine, N-methylpiperazine and L-
prolinomethylester. We synthesized enamines bearing different amines, such as
piperidine or pyrrolidine, but further reaction with azidopyrone 1 leaded to aromatic
triazoles. This behavior has already been reported14 and it's probably due to the
increased basicity of those amines. Alifatic amidines has been synthesized by one
pot reaction between the corresponding aldehyde, morpholine and azidopyrone 1. In
this case, however, isolation of the triazoline intermediate 3 was necessary in order
to obtain good yields in amidine 4 (Scheme 3)
14 S. Cilloni, D. Pocar, L. M. Rossi and P. Trimarco, Journal of Chemical Research, Synopses,
1980, 1, 4
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During our preliminary experiment the 6-methyl-4-(1-morpholino-2-
phenylethylideneamino)-2H-pyran-2-one 4 was refluxed in piperidine as solvent
and after 17 hours turned into a mixture of substituted pyridines 5 and 6 in the ratio
of 1:2 (Scheme 4).
10
R1
O
H
+ HN O +
OO
N3
CH3
Ph-H
HR1
H
N
N
N
N
OO CH3
O
nPrOH
reflux
2h
N
O
O
CH3
R1
N
O
2j CH3
2k CH3SCH2
H3C
H3C
CH3
4
12
2l
Scheme 4 
Their spectral data were in agreement with the proposed structures and with
available data in literature for similar substitution pattern15. 13C-NMR spectrum of
2-pyridineacetamide 6 showed the signals related to CH-3 at about 119 ppm and to
amide carbonyl group at 169 ppm, the latter was validated also by IR stretching at
1630 cm-1. 1H NMR was characterized by three singlets (2.06 δ, 3.80 δ and 6.87 δ )
associated with CH3 on C-4, CH2 linked to amide carbonyl group on C-2 and H-3 on
C-3, respectively. In 1H NMR spectrum of 4,6-dimethylpyridine derivative 5 three
singlets at 2.05, 2.44 and 6.70 δ associated respectively with the methyl groups
linked to C-4 and C-2 and H-3 of the pyridine ring appeared diagnostic.
It can be quite reasonable to assume that 5 and 6 come from two different pathways,
which seem competitive in these reaction conditions (Scheme 5).
15 (a) C.D. Johnson, Comprehensive Heterocyclic Chemistry, A. J. Boulton and A. Mc Killop, Ed,
Pergamon, Oxford, 1984, 2, 117-124 and ref. cited therein. (b) Atlas of Spectral Data and
Physical Constants for Organic Compounds, 2nd Edition, J. G. Grasselli, and W. M.  Ritchey,
Ed. CRC Press, Cleveland, 1975, 4, 373-408. (c) C. J. Pourchert, J. Behnke, The Aldrich Library
of 13 C and 1H FT-NMR Spectra, 1st Edition, Aldrich Chemical Co., Milwaukee, 1993. (d) E.
Pretsch, J. Seibl, T. Clerc, W. Simon, Tables of Spectral Data for Structure Determination of
Organic Compounds, 2nd Edition, Springer-Verlag, New York, 1989.
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According to path a the pyridine amide derivative 6a resulted from the nucleophilic
attack of the amino group on the C-2 position of 2-pyranone nucleus followed by
ring opening and intra molecular cyclization, by way of the C-α amidinic carbanion
intermediate. According to path b the formation of 4,6-dimethylpyridine derivative
5a is rationalized as follows: addition of the amino group on the C-6 position of the
pyran-2-one nucleus, ring opening, followed by ring closure of the C-α amidinic
carbanion intermediate. The final product 5a was achieved after decarboxylation
step, as it is well known on the pyridine nucleus16, and amino group elimination
favored by aromatization to give pyridine ring.
16 T. Naito, R. Dohmori, T. Kotake, Chem. Pharm. Bull. 1964, 12, 588-90. 
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To confirm the proposed mechanism and to determine the best conditions to
enhance the yield of amide derivatives 6 we decided to investigate the reaction
closely (Scheme 6).
Scheme 6 
The reaction of the amidine 4 in piperidine as solvent at 60°C for 35 hours afforded
a reaction mixture containing 15% of amide 6 and pyridine 5 in 85% yield. During
subsequent experiments the piperidine and the amidine 4 were mixed in a sealed
tube and put in a preheated oil bath at 170°C and then at 200°C. Significant
improvements in yields were achieved by these reaction conditions. Just in 5 hours
at 170°C the major isomer was shown to be the 2-pyridineacetamide 6 (88%) beside
the 4,6-dimethylpyridine 5 in 12% yield. The ratio of 5 and 6 in the mixture was
determined by 1H-NMR analysis. In fact the different hydrogen shift on C-3 for 5
and 6 (6.70 δ and 6.87 δ respectively) allowed a clear difference between the two
pyridines obtained. Performing the reaction at 200°C, the amide derivative 6 was
only obtained.
These results point out that under mild conditions the nucleophylic addition on the
C-6 (path b) prevails, but at higher temperatures the addition product to C-2
position (path a) is favored. In order to verify that 5 does not arise from hydrolysis
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of amide 6, this product was reacted 35 hours at 60°C under the most favorable
conditions to 5 formation. The 1H-NMR spectrum of the crude mixture showed only
the signals of amide derivative 6a, thus confirming the independence of paths
leading to 5 and 6, respectively. We thought therefore to extend the reaction to all
the amidines reported in Scheme 1 and perform the reaction at 200°C (Scheme 7)
Scheme 7
Amidines 4 were mixed with an excess of secondary amine HNR22 in a sealed tube
and put in preheated oil bath at 200°C. The transformation required a reaction time
within 2-4 hours. 
Probably the high temperature of the reaction mixture was responsible in some
cases of low yields besides the formation of polymerised material. The best results
were achieved from the amidines 4 bearing an aromatic or better an haloaromatic
substituent and suggest that the yields of the amide derivatives 6 are depending on
easy deprotonation of methylene group bound to aryl substituents. Under these
reaction conditions most of the amidines 4 were converted into the expected
pyridineacetamides 6, however amidines bearing a p-methoxyphenyl, methyl or
methylsulfanylmethyl substituent gave a mixture of two amide derivatives 6 and 7.
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Confirmation of the structures was obtained from both 1H and 13C NMR of the
purified materials obtained in a ratio of about 2:1, respectively. It can be reasonably
assumed that amides 7 arise from a transamidation reaction of the corresponding
amidines or of their intermediate compounds. Amine exchange reaction has already
been studied17 on formamidines. Considering that the key synthetic step in the
formation of pyridine nucleus was the final cyclization of the C-α amidinic
carbanion intermediate, the difficult formation of ethyl, methylsulfanylethyl or even
p-methoxyphenyl carbanions could explain the low yield of the desired amides 6
and the concomitant formation of the amides 7. In order to verify that the amides 7
do not arise from nucleophilic attack on C-α of the pyridine nucleus18, the amide 6 
5-methyl substituted was treated with a large amount of piperidine and heated in a
sealed tube for 4 hours, under the same previously adopted conditions. 1H NMR
analysis of the crude reaction mixture showed only the amide 6 peaks and
confirmed transamidation hypothesis.(Scheme 8)
Scheme 8
Results of reactions between amidines 4 and a secondary amine are collected in
Table 1.
17 Furth, P. S.; Reitmann, M. S.; Cook, A. F. Tetrahedron Lett., 1997, 38, 5403-5406
18 Vorbrüggen, H. Adv. Heterocycl. Chem., 1990, 49, 142.
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Table 1 
R1 NR2 NR 22 Time(h)
6(%)* 7 (%)*
C6H5 morpholine piperidine 4 70
C6H5 morpholine N-methylpiperazine 3 72
C6H5 morpholine morpholine 2.5 85
C6H5 morpholine diethylamine 2 65
C6H5 morpholine N-benzylpiperazine 2 65
C6H5 prolinomethylester morpholine 2 35
pCH3-C6H4 morpholine piperidine 4 67
pOCH3-C6H4 morpholine piperidine 7 46 15
pCl-C6H4 morpholine piperidine 2,5 70
pCl-C6H4 morpholine N-methylpiperazine 2,5 73
pBr-C6H4 morpholine piperidine 2,5 60
pBr-C6H4 morpholine N-methylpiperazine 2,5 65
pBr-C6H4 morpholine morpholine 2,5 75
pBr-C6H4 morpholine N-carbethoxypiperaz. 4 53
pBr-C6H4 N-methylpiperazine N-methylpiperazine 2 66
pF-C6H4 morpholine piperidine 2,5 65
pF-C6H4 morpholine N-methylpiperazine 2,5 70
2,4 diCl-C6H4 morpholine N-methylpiperazine 4 65
CH3 morpholine piperidine 4 40 20
CH3 morpholine N-methylpiperazine 3 57 26
CH3SCH2 morpholine N-methylpiperazine 2 42 23
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N
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2
O
R1 NR2 NR 22 Time(h)
6(%)* 7 (%)*
morpholine N-methylpiperazine 2 35 Not
isolate
d
(*yield calculated on isolated product)
Concluding, these results demonstrated the double reactivity of the amidines
functionalized at iminic nitrogen with pyran-2-one nucleus and the synthetic
potentiality of the substrate. In this case the amidines became part of a wide chapter
of the synthetic methodology to obtain functionalized pyridines.
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3. Experimental
A list of products described in this experimental section is represented in Table2
Table 2
Class N° R1 NR2 HNR 22
Enamines 2 2a
2b
2c
2d
2e
2f
2g
2h
2i
Ph
p-CH3Ph
p-ClPh
p-BrPh
p-BrPh
p-FPh
2,4-diClPh
p-CH3OPh
Ph
morpholine
morpholine
morpholine
morpholine
N-methylpip.
morpholine
morpholine
morpholine
Prolinomethyleste
r
Triazolines 3 3a
3b
3c
3d
3e
3f
3g
3h
3i
3j
3k
3l
Ph
p-CH3Ph
p-ClPh
p-BrPh
p-BrPh
p-FPh
2,4-diClPh
p-CH3OPh
Ph
CH3
CH3SCH2
morpholine
morpholine
morpholine
morpholine
N-methylpip.
morpholine
morpholine
morpholine
Prolinomethyleste
r
morpholine
morpholine
morpholine
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R1
NR2
N
N
N
R1
R2N
OO
H3C
H3C
CH3
Class N° R1 NR2 HNR 22
Amidines 4 4a
4b
4c
4d
4e
4f
4g
4h
4i
4j
4k
4l
Ph
p-CH3Ph
p-ClPh
p-BrPh
p-BrPh
p-FPh
2,4-diClPh
p-CH3OPh
Ph
CH3
CH3SCH2
morpholine
morpholine
morpholine
morpholine
N-methylpip.
morpholine
morpholine
morpholine
prolinomethylester
morpholine
morpholine
morpholine
Pyridines 5 5a Ph morpholine
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NR2N
R1
R1
N
O
R2N
O
H3C
H3C
CH3
Class N° R1 NR2 HNR 22
Pyridines 6 6a
6b
6c
6d
6e
6f
6g
6h
6i
6j
6k
6l
6m
6n
6o
6p
6q
6r
6s
6t
6u
6v
6w
Ph
Ph
Ph
Ph
Ph
Ph
pCH3Ph
pClPh
pClPh
pBrPh
pBrPh
pBrPh
pBrPh
pBrPh
pBrPh
pF-Ph
pF-Ph
2,4-diClPh
pCH3O-Ph
CH3
CH3
CH3SCH2
morpholine
morpholine
morpholine
morpholine
morpholine
prolinomethylester
morpholine
morpholine
morpholine
morpholine
morpholine
morpholine
morpholine
morpholine
N-methylpip.
morpholine
morpholine
morpholine
morpholine
morpholine
morpholine
morpholine
morpholine
piperidine
N-methylpip.
N-benzylpip.
morpholine
diethylamine
morpholine
piperidine
piperidine
N-methylpip.
piperidine
N-methylpip.
N-carboxyethylpip.
morpholine
diethylamine
N-methylpip.
piperidine
N-methylpip.
N-methylpip.
piperidine
piperidine
N-methylpip.
N-methylpip.
N-methylpip.
Pyridines 7 7a
7b
7c
7d
CH3
CH3
CH3SCH2
pCH3O-Ph
piperidine
N-methylpip.
N-methylpip.
piperidine
piperidine
N-methylpip.
N-methylpip.
piperidine
Melting points were determined using a Buchi 510 (capillary) or an Electrothermal
9100 apparatus and are uncorrected. IR spectra were measured using a JASCO IR
Report 100 instrument. 1H and 13C-NMR spectra (tetramethylsilane as internal
standard) were recorded with EM Varian Gemini 200, Bruker AC 200 and Bruker
20
NR2N
R1
O
NR22
H3C
H3C
CH3
NR2N
R1
O
NR22
Avance 300 Spectrometers. J-Values are given in Hz for solutions in CDCl3.
Column chromatography was performed on Kieselgel 60 (Merck) 0.063-0.200 mm
with eluents and ratios indicated in Experimental.
Materials. 2,4-Dichlorophenylacetaldehyde, azide 119 and enamines 2a, b, d20a,
2c20b, 2f, 2h20c and 2i20d have already been described. 4,5-dihydrotriazoles 3a-d, 3f,
3h, 3j and amidines 4a-d, 3f, 3h, 3j are known compounds6.
When referring to derivatives 2i, 3i, 4i, and 6f stereochemistry will not be indicated
as it's tipical of the commercial aminoacid pyrrolidine-2S-carboxylic acid methyl
ester and the stereocenter is not involved in the reaction. For compounds 3l, and 6w
the stereochemistry is that of the commercial racemic 2,6-dimethyl-hept-5-enal.
Quantum mechanical computations has been performed using programs GAMESS21
version 20 June 2002 (R2) and PCGAMESS22 version 6.2. Geometries has been
completely optimized at RHF level using the 6-31G**23 basis set; minima where
confirmed by vibrational analysis and no imaginary frequencies were observed;
linear dependence threshold (QMTTOL) was set at 1x10-7, HONDO/Rys integrals
were used for all integrals (INTTYP=HONDO) and DIIS converger was used
instead that SOSCF. Geometries has been optimized using GAMESS on a HP64000
machine running HP-UX at CILEA.24.
Electrostatic potential calculations has been performed on a Linux-PC using
PCGAMESS , while plots of electrostatic potential mapped on isodensity surfaced
have been realized with the program GOPEMOL25.
(E) 1-[2-(4-bromophenyl)-ethenyl]-4-methyl-pyperazine 2e
The procedure followed is identical to that described for (E) 4-[2-(2,4-
19 M. Cervera, M. Moreno-Mañas and R. Pleixats, Tetrahedron, 1990, 46, 7885. 
20 a) N. L. J. M. Broekhof, F. L. Jonkers and A. van der Gen, Tetrahedron Lett., 1979, 2433. 
b) K. Stamos, Tetrahedron Lett., 1982, 23, 459. 
c) G. Crispi, P. Giacconi, E. Rossi and R. Stradi, Synthesis, 1982, 787.
d) M. Costa, G. P. Chiusoli, R. Gaetti, B. Gabriele, G. Salerno, Russ. Chem. Bl., 1998, 47(5),
936-940. 
21GAMESS version 20 June 2002 (R2) from Iowa State University, M.W.Schmidt, K.K.Baldridge,
J.A.Boatz, S.T.Elbert, M.S.Gordon, J.H.Jensen, S.Koseki, N.Matsunaga,  K.A.Nguyen, S.J.Su,
T.L.Windus, together with M.Dupuis, J.A.Montgomery,   J.Comput.Chem., 1993, 14, 1347-1363.
22 Alex A. Granovsky, www http://classic.chem.msu.su/gran/gamess/index.html
23M. J. Frisch, J. A. Pople and J. S. Binkley, J. Chem. Phys., 1984, 80, 3265, and ref. cited therein. 
24 Centro Interuniversitario Lombardo per l'elaborazione Avanzata, Via R. Sanzio, 4 20090 Segrate,
Mi.
25 a)L. Laaksonen, J. Mol. Graph., 1992, 10, 33-34. 
b)D.L. Bergman, L. Laaksonen and A. Laaksonen, J. Mol. Graph. Model., 1997, 15, 301-306.
21
Dichlorophenyl)-ethenyl]-morpholine. Yellow pale oil, 90% yield.
1H NMR δ 2.35(3H, s, CH3), 2.47-2.52 (4H, m, CH2NCH2 linked to CO), 3.08-3.13
(4H, m, CH2NCH2), 5.33 (1H, d, J=13.9 Hz, vinylic H), 6.66 (1H, d, J=13.9 Hz,
vinylic H), 7.06-7.32  (4H, 2 x d, AB system, J=8.8Hz, ArH). 
(E) 4-[2-(2,4-Dichlorophenyl)-ethenyl]-morpholine 2g
2,4-Dichlorophenylacetaldehyde (5.9 g, 30 mmol) and morpholine (2.7 ml,
30mmol) were dissolved in anhydrous toluene (60 ml) and heated at reflux with
azeotropic removal of water. The reaction progress was checked by IR spectroscopy
until aldehyde absorption disappeared. The toluene solution was dried with Na2SO4,
filtered and the solvent removed under reduced pressure. After IR and 1HNMR
analysis and without further purification, the pale yellow oily residue (7 g, 90%)
was reacted with azide. IR (liquid film) νmax 1633 cm-1; 1H NMR δ 3.05-3.15 (4H,
m, CH2NCH2), 3.72-3.80 (4H, m, CH2OCH2), 5.63 (1H, d, J=13.9 Hz, vinylic H),
6.60 (1H, d, J=13.9 Hz, vinylic H), 7.07-7.34 (3H, m, ArH). Anal. Calcd. for
C12H13Cl2NO: C, 55.83; H, 5.08; N, 5.43; found: C, 55.64; H, 4.96; N, 5.31.
4-[4-(4-Bromophenyl)-5-(4-methyl-piperazin-1-yl)—4,5-dihydro-[1,2,3]-triazol-
1-yl]-6-methyl--pyran-2-one 3e
Azide 1 (3.0 g, 20 mmol) was dissolved in benzene (20 ml) and an equimolar
amount of enamine 2, dissolved in benzene (20 ml), was added dropwise. The
mixture was stirred overnight at room temperature. (TLC cyclohexane/EtOAc, 1:9)
The white precipitate was filtered off and recrystallized from benzene to give pure
3e as white crystals (5.97 g, 73%); mp 92°C (decomp.); IR (Nujol) νmax 1717 (C=O)
cm-1; 1H NMR δ 2.32 (3H, s, N-CH3), 2.33 (3H, s, CH3); 2.48 (8H, m, (CH2NCH2)2
); 4.62 (1H, d, J=3.3 Hz, H-5); 5.57 (1H, d, J=3.3 Hz, H-4); 5.73 (1H, s, H-3
pyranone); 6.78 (1H, s, H-5 pyranone); 6.88 and 7.53 (4H, 2 x d, AB system, J=8.4
Hz, ArH).
4-[4-(2,4-Dichlorophenyl)-4,5-dihydro-5-morpholino-1H-1,2,3-triazol-1-yl]-6-
methyl-2H-pyran-2-one 3g
Azide 1 (3.0 g, 20 mmol) was dissolved in benzene (20 ml) and an equimolar
amount of enamine 2g, dissolved in benzene (20 ml), was added dropwise. The
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mixture was stirred overnight at room temperature. (TLC cyclohexane/EtOAc, 1:9)
The white precipitate was filtered off and recrystallized from benzene to give pure
3g as white crystals (5.97 g, 73%); mp 154°C (decomp.); IR (Nujol) νmax 1716
(C=O) cm-1; 1H NMR δ 2.33 (3H, s, CH3); 2.43-2.52 (4H, m, CH2NCH2); 3.65-3.75
(4H, m, CH2OCH2); 4.57 (1H, d, J=3.3 Hz, H-5); 5.98 (1H, d, J=3.3 Hz, H-4); 5.73
(1H, s, H-3 pyranone); 6.77 (1H, s, H-5 pyranone); 6.57 (1H, d, J=8.4 Hz, ArH-6’);
7.25 (1H, dd, J=8.4 Hz and 2.2 Hz, ArH-5’); 7.52 (1H, d, J=2.2 Hz, ArH-3’). Anal.
Calcd. for C18H18Cl2N4O3: C, 52.83; H, 4.43; N, 13.69; found: C, 52.94; H, 4.51; N,
13.42.
1-[3-(6-methyl-2-oxo-2H-pyran-4-yl)-5-phenyl-4,5-dihydro-3H-[1,2,3]triazol-4-
yl]-pyrrolidine-2-carboxylic acid methyl ester 3i
Azide 1 (2.31 g, 10 mmol) was dissolved in benzene (20 ml) and an equimolar
amount of enamine 2i, dissolved in benzene (20 ml), was added dropwise. The
mixture was stirred overnight at room temperature. (TLC cyclohexane/EtOAc, 3:7) .
Solvent was evaporated in vacuo to give 3i as pale yellow oil; at 1H NMR the
product resulted pure at 70%; further purification was not possible due to it's
lability. 1H NMR δ 2.27 (3H, s, CH3); 1.88-2.45 (6H, m, pyrrolidine); 3.66 (3H, s,
OCH3); 3.81-3.89 (1H, m, H on C*); 5.03 (1H, d, J=2.2 Hz, H-5); 5.72 (1H, d, J=2.2
Hz, H-4); 5.77 (1H, s, H-3 pyranone); 6.79 (1H, s, H-5 pyranone); 7.04-7.25 (5H,
m, ArH).
4-(4,5-Dihydro-4-methylsulfanylmethyl-5-morpholino-1H-1,2,3-triazol-1-yl)-6-
methyl-2H-pyran-2-one 3k
A benzene solution (20 ml) of morpholine (1.74 g, 20 mmol) was added dropwise to
a stirred solution of azide 1 (3g, 20 mmol) and 3-methylsulfanylpropionaldehyde
(2.08 g, 20mmol) in benzene (30 ml). The mixture was stirred at r.t. until the
starting azide disappeared (about 3h) (TLC cyclohexane/EtOAc, 1: 9). The solution
was dried with Na2SO4, filtered and the filtrate evaporated under reduced pressure.
The residue was dissolved in CH2Cl2 and by adding iPr2O afforded pure 3k (4.8 g,
74%) as cream needles; mp 99°C (decomp.); IR (Nujol) νmax 1727 (C=O) cm-1; 1H
NMR δ 2.20 (3H, s, CH3S), 2.29 (3H, s, CH3), 2.21-2.45 (5H, m, CH2NCH2 and 1 H
of CH2S linked to C-4), 2.99 (1H, dd, J=4.3 Hz and Jgem=13.8 Hz, H of CH2S linked
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to C-4), 3.60-3.70 (4H, m, CH2OCH2), 4.65 (1H, d, Jtrans=3.0 Hz, H-5), 4.75 (1H,
ddd, Jtrans=3.0 Hz, J=4.3 Hz and J=7.3 Hz, H-4), 5.77 (1H, s, H-3 pyranone), 6.71
(1H, s, H-5 pyranone). Anal. Calcd. for C14H20N4O3S: C, 51.84; H, 6.21; N, 17.27;
found C, 51.89; H, 6.27; N, 16.98.
4-[4-(1,5-dimethyl-hex-4-enyl)-5-morpholin-4-yl-4,5-dihydro-[1,3,4]triazol-1-
yl]-6-methyl-pyran-2-one 3l
Azide 1 (2.0 g, 13 mmol) was dissolved in benzene (40 ml) with equimolar amounts
of racemic 2,6-dimethyl-hept-5-enal and morpholine. The mixture was stirred
overnight at room temperature (TLC cyclohexane/EtOAc, 3:7) Evaporation of the
solvent gave 3l as a yellow oil (85%); 1H NMR δ 0.75-0.87 (3H, dd, J=6.59 CH3 on
C*); 1.22-1.52 (2H, m, CH2); 1.63 (3H, s, CH3), 1.71 (3H, s, CH3),1.97-2.24 (2H, m,
CH2), 2.30 (3H, s, CH3); 2.29-2.36 (4H, m, CH2NCH2); 3.63-3.68 (4H, m,
CH2OCH2); 4.39 (1H, m, H-5); 4.52 (1H, m, H-4);5.09 (1H, m, vinyl H); 5.69 (1H,
s, H-3 pyranone); 6.74 (1H, s, H-5 pyranone).
4-[2-(4-Bromophenyl)-1-(4-methyl-piperazin-1-yl)-ethylideneamino]-6-methyl-
pyran-2-one 4e
Dihydrotriazole 3e (10 mmol) was dissolved in n-propanol (70 ml) and heated
under reflux until the starting compound disappeared (2 hours), progress of the
reaction being followed by TLC (cyclohexane/ EtOAc 1:9). The solvent was
removed in vacuo. The crude residue was taken up with CH2Cl2 and insoluble
precipitate was filtered off. The filtrate was evaporated under reduced pressure to
give a residue, which was crystallized from n.PrOH to afford the amidine 4e (70%)
as yellow plates; mp149°C; IR (Nujol) νmax 1715 (C=O) cm-1; 1H NMR δ 2.17 (3H,
s, CH3); 2.31 (3H, s, NCH3); 2.34-2.37 (4H, m, CH2NCH2); 3.51 (4H, m,
CH2NCH2); 3.76 (2H, s, CH2); 5.24 (1H, s, H-3), 5.64 (1H, s, H-5); 7.01 and 7.48
(4H, 2 x d, AB system, J=8.4 Hz, ArH) ;13C NMR δ 19.9 (CH3 pyrone), 33.8 (CH2),
44.9 (CH2NCH2), 45.9 (N-CH3), 54.6 (CH2NCH2), 95.8 (pyrone C-5), 104.6 (pyrone
C-3), 120.99 (Ar C-Br), 129.4 (Ar CH), 132.2 (Ar CH), 134.2 (Ar C-CH2), 155.7
(pyrone C-6), 161.41 (pyrone C-4), 164.6 (amidinic C), 164.9 (CO).
4-[2-(2,4-Dichlorophenyl)-1-morpholino-ethylideneamino]-6-methyl-2H-pyran-
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2-one 4g
Dihydrotriazole 3g (4.1 g,10 mmol) was dissolved in n.propanol (70 ml) and heated
under reflux until the starting compound disappeared (2 hours), progress of the
reaction being followed by TLC (cyclohexane/ EtOAc 4:6). The solvent was
removed in vacuo. The crude residue was taken up with CH2Cl2 and insoluble
precipitate was filtered off. The filtrate was evaporated under reduced pressure to
give a residue, which was crystallized from n.PrOH to afford the amidine 4g (2.67
g, 70%) as orange plates; mp137°C; IR (Nujol) νmax 1715 (C=O) cm-1; 1H NMR δ
2.18 (3H, s, CH3); 3.41-3.65 (8H, m, morpholine); 3.78 (2H, s, CH2); 5.23 (1H, s,
H-3), 5.63 (1H, s, H-5); 7.10 (1H, d, J=8.4 Hz, ArH-6’), 7.29 (1H, dd, J=8.4 Hz and
J=1.8 Hz, ArH-5’), 7.44 (1H, d, J=1.8 Hz, ArH-3’). Anal. Calcd. for C18H18Cl2N2O3:
C, 56.71; H, 4.76; N, 7.35. Found: C, 56.68; H,4.74; N, 7.41.
1-[1-(6-methyl-2-oxo-2H-pyran-4-ylimino)-2-phenyl-ethyl]-pyrrolidine-2-
carboxylic acid methyl ester 4i
Dihydrotriazole 3 (7 mmol) was dissolved in n-propanol (50 ml) and heated under
reflux until the starting compound disappeared (2 hours), progress of the reaction
being followed by TLC (cyclohexane/ EtOAc 3:7). The solvent was removed in
vacuo. The crude residue was taken up with CH2Cl2 and insoluble precipitate was
filtered off. The filtrate was evaporated under reduced pressure to give a yellow oil
that was purified by chromatography on silica gel (cyclohexane/ EtOAc 3:7) to yeld
1.1g (43%) of pure 4i as a pale yellow oil; IR (Nujol) νmax 1715 (C=O) cm-1; 1H
NMR δ 1.88-2.19 (4H, m, pyrrolidine); 2.13 (3H, s, CH3); 3.38-3.41 (2H, m, CH2);
3.76 (3H, s, OCH3); 3.79 (2H, s, CH2Ph); 4.52-4.56 (1H, m, H on C*); 5.28 (1H, s,
H-3), 5.56 (1H, s, H-5); 7.20-7.38 (5H, m, ArH);13C NMR δ 19.9 (CH3 pyrone);
24.8 and 29.4 (2 x CH2 pyrrolidine); 35.4 (CH2Ph); 47.6 (CH2N); 52.2 (OCH3); 60.3
(*CH); 96.4 (pyrone C-5); 105.1 (pyrone C-3); 127.0 (Ar CH); 128.0 (Ar CH);
129.1 (Ar CH); 134.6(Ar C); 155.1 (pyrone C-6), 161.4 (pyrone C-4), 164.5
(amidinic C), 165.2 (CO pyrone); 173.2 (COO). 
6-Methyl-4-(3-methylsulfanyl-1-morpholino-propylideneamino)-2H-pyran-2-
one 4k
A solution of dihydrotriazole 3 (3.2 g, 10 mmol) was refluxed in toluene (60 ml),
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progress of the reaction being followed by TLC (cyclohexane/EtOAc, 1:9). After
disappearance of the starting material (3 hours) the solvent was removed in vacuo
and the oily residue crystallized by adding of Et2O to give 4 (2.46 g, 83%) as cream
needles; mp 111°C; IR (Nujol) νmax 1690 (C=O) cm-1; 1H NMR δ 2.08 (3H, s, CH3);
2.22 (3H, s, SCH3), 2.56-2.70 (4H, m, 2 x CH2), 3.45-3.53 (4H, m, CH2NCH2);
3.70-3.78 (4H, m, CH2OCH2); 5.28 (1H, s, H-3), 5.67 (1H, s, H-5). Anal Calc. for
C14H20N2O3S: C, 56.74; H, 6.80; N, 9.45; found: C, 56.65; H, 6.73; N, 9.30.
4-(4,8-dimethyl-1-morpholin-4-yl-non-7-enylideneamino)-6-methyl-pyran-2-
one 4l
Dihydrotriazole 3 (13 mmol) was dissolved in n.propanol (70 ml) and heated under
reflux until the starting compound disappeared (2 hours), progress of the reaction
being followed by TLC (cyclohexane/ EtOAc 3:7). The solvent was removed in
vacuo. The crude residue was taken up with CH2Cl2 and insoluble precipitate was
filtered off. The filtrate was evaporated under reduced pressure to give 4e as a
yellow oil (65%); 1H NMR δ 0.87 (3H, d, J=6.59 CH3 on C*); 1.23-1.31 (2H, m,
CH2); 1.60 (3H, s, CH3); 1.70 (3H, s, CH3);1.95-2.06 (2H, m, CH2); 2.21 (3H, s,
CH3); 2.27-2.37 (2H, m, CH2); 3.47-3.52 (4H, m, CH2NCH2); 3.70-3.74 (4H, m,
CH2OCH2); 5.03 (1H, m, vinyl H); 5.20 (1H, s, H-3 pyranone); 5.60 (1H, s, H-5
pyranone).
Reaction of the amidine 4a with piperidine at reflux. Synthesis of 4-(4,6-
dimethyl-3-phenyl-pyridin-2-yl)-morpholine 5a and 2-(4-methyl-6-morpholino-
5-phenyl-pyridin-2-yl)-1-piperidin-1-yl-ethanone 6a 
Amidine 4a (R1=Ph, HNR2=morpholine, 1.56 g, 5 mmol) was suspended in
piperidine (15 ml). The reaction mixture was refluxed until disappearance (TLC
monitoring) of the starting compound (17 hours). The amine excess was removed in
vacuo and the crude residue chromatographed on a silica gel column, eluent
EtOAc/cyclohexane (4:6). Two fractions were collected: a first minor fraction
containing the pyridine derivative 5a and a second fraction containing the pyridine
amide 6a:
5a: white crystals from iPr2O, 0.39 g, yield 29%, mp 87°C; 1H NMR δ 2.05 (3H, s,
p-CH3); 2.44 (3H, s, o-CH3); 2.92-3.02 (4H, m, CH2NCH2); 3.43-3.50 (4H, m,
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CH2OCH2); 6.70 (1H, s, H-3); 7.2-7.44 (5H, m, ArH); 13C NMR δ 20.8 (p-CH3);
24.5 (o-CH3); 50.1 (CH2NCH2); 67.4 (CH2OCH2); 119.1 (m-CH); 127.3, 128.8,
130.6, (ArCH); 125.0, 138.8, 147.2 (ArCqu); 155.2 (C bound to o-CH3); 160.0 (C
bound to morpholino group). Anal. Calcd. for C17H20N2O: C, 76.09; H, 7.51; N,
10.44; found: C,76.01; H, 7.62; N,10.33. 
6a: cream crystals from petroleum ether, 1.14 g, yield 60%, mp 112°C; IR (Nujol)
νmax 1630 (C=O) cm-1; 1H NMR δ 1.45-1.70 (6H, m, CH2CH2CH2); 2.06 (3H, s, p-
CH3); 2.90-3.00 (4H, m, CH2NCH2); 3.42-3.50 (4H, m, CH2OCH2); 3.54-3.69 (4H,
m, O=C-N(CH2)2); 3.80 (2H, s, CH2); 6.87 (1H, s, H-3); 7.29-7.47 (5H, m, ArH);
13C NMR δ 20.6 (p-CH3); 24.6, 25.6, 26.5 (CH2CH2CH2); 43.0, 43.6 (O=C-
N(CH2)2); 47.7 (CH2-C=O); 49.7 (CH2NCH2); 66.9 (CH2OCH2), 118.9 (C-3); 127.1,
128.5, 130.1 (ArCH); 125.6, 138.0, 147.4 (ArCqu), 152.2 (C-2); 159.6 (C-6); 169.0
(C=O). Anal. Calcd. for C23H29N3O2: C, 72.79; H, 7.70; N, 11.07; found: C, 72.67;
H, 7.63; N,11.09.
General procedure for the preparation of amide derivatives 6 and 7
Amidines 4 (5 mmol) mixed with a large amount of the appropriate amine (100
mmol) in a sealed tube were put in a preheated oil bath at 200°C and heated for at
least 2 hours. Afterwards, the progress of the reaction was monitored by TLC every
30 minutes, until disappearance of the starting amidine 4.
The amine excess was removed in vacuo and the residue was chromatographed on
silica gel affording compound 6 and in some cases minor amounts of compound 7
(eluent see later) The yields of isolated and purified products 6 and 7 are listed in
Table 1.
2-(4-Methyl-6-morpholino-5-phenyl-pyridin-2-yl)-1-piperidin-1-yl-ethanone 6a
(EtOAc/cyclohexane, 4:6). Analytical data are shown above.
2-(4-Methyl-6-morpholino-5-phenyl-pyridin-2-yl)-1-(4-methyl-pyperazin-1-yl)-
ethanone 6b
(MeOH/EtOAc, 7:3); cream plates from iPr2O; mp 110°C; IR (Nujol) νmax 1620
(C=O) cm-1; 1H NMR δ 2.05 (3H, s, p-CH3); 2.33 (3H, s, H3C-N); 2.35-2.47 (4H, m,
H3C-N(CH2)2); 2.87-2.96 (4H, m, CH2NCH2); 3.38-3.48 (4H, m, CH2OCH2); 3.67-
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3.82 (4H, m, O=CN(CH2)2); 3.80 (2H, s, CH2); 6.85 (1H, s, H-3); 7.20-7.42 (5H, m,
ArH). 13C NMR δ 20.9 (p-CH3); 42.0 and 43.8 (H3C-N(CH2)2); 46.3 (H3C-N); 46.6
(CH2-C=O); 50.1 (CH2NCH2); 55.0 and 55.6 (O=C-N(CH2)2); 67.2 (CH2OCH2);
119.3 (C-3); 127.5, 128.9, 130.4 (ArCH); 126.2, 138.3, 147.9 (ArCqu); 152.3 (C-2);
160.1 (C-6); 169.5 (C=O). Anal. Calcd. for C23H30N4O2: C, 70.02; H, 7.66; N, 14.20;
found: C, 69.87; H, 7.54; N,13.99.
2-(4-Methyl-6-morpholino-5-phenyl-pyridin-2-yl)-1-(4-methyl-N-benzyl-
pyperazin-1-yl)-ethanone 6c
(MeOH/EtOAc, 7:3); cream plates from iPr2O; mp 141°C; IR (Nujol) νmax 1636
(C=O) cm-1; 1H NMR δ 2.07 (s, 3H, CH3); 2.44 (m, 4H, CH2N(benzyl)CH2); 2.95
(m, 4H, CH2NCH2);3.47 (m, 4H, CH2OCH2); 3.54 (s, 2H, CH2Ph); 3.72 (m, 4H,
CH2N(CO)CH2); 3.81 (s, 2H, CH2CO); 6.83 (s, 1H, H-meta); 7.38 (m, 10H, ArH);
13C NMR δ 20.6 (CH3-para); 41.9 and 43.5 (H3C-N(CH2)2); 46.6 (CH2-C=O); 49.7
(CH2NCH2); 52.8 and 53.3 (O=C-N(CH2)2); 63.0 (CH2-Ph); 66.9 (CH2OCH2); 118.9
(CH-meta); 127.1, 127.4, 128.4, 128.5, 129.23, 130.1 (arom. CH); 125.7, 137.7,
138.0 and 147.5 (arom Cqu); 152.0 (C-2, N=C-CH2)); 159.7 (C-6 linked to
Morph.); 169.1 (C=O).
2-(4-Methyl-6-morpholino-5-phenyl-pyridin-2-yl)-1-morpholin-4-yl-ethanone
6d
(EtOAc); orange plates from iPr2O; mp 134°C; IR (Nujol) νmax 1634 (C=O) cm-1; 1H
NMR δ 2.06 (3H, s, p-CH3); 2.90-2.98 (4H, m, CH2NCH2); 3.42-3.50 (4H, m,
CH2OCH2); 3.60-3.77 (8H, m, O=CN(CH2)2 and CH2OCH2); 3.80 (2H, s, CH2); 6.87
(1H, s, H-3); 7.26-7.45 (5H, m, ArH). 13C NMR δ 20.6 (p-CH3) 42.3 and 43.3
(O=C-N(CH2)2); 47.0 (CH2-C=O); 49.7 (CH2NCH2); 66.9 (2 x CH2OCH2), 119.0
(C-3); 127.2, 128.5, 130.0 (ArCH); 125.9, 137.8, 147.6 (ArCqu), 151.7 (C-2); 159.7
(C-6); 169.4 (C=O).Anal. Calcd. for C22H27N3O3: C, 69.27; H, 7.13; N, 11.02;
found: C, 69.02; H, 7.16; N, 10.81.
N,N-Diethyl-2-(4-methyl-6-morpholino-5-phenyl-pyridin-2-yl)-acetamide 6e
(EtOAc/cyclohexane, 7:3); chestnut plates from iPr2O; mp 77°C; IR (Nujol) νmax
1631 (C=O) cm-1; 1H NMR d 1.13-1.25 (6H, m, 2 x CH3CH2); 2.08 (3H, s, p-CH3);
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2.93-3.01 (4H, m, CH2NCH2); 3.43-3.50 (4H, m, CH2OCH2); 3.52-3.63 (4H, m, 2 x
CH2CH3); 3.79 (2H, s, CH2C=O); 6.88 (s; 1H, H-3); 7.27-7.43 (5H, m, ArH); 13C
NMR d 13.1 (CH3); 14.4 (CH3); 20.5 (p-CH3); 40.3 (CH2); 42.6 (CH2); 43.2
(CH2C=O); 49.7 (CH2NCH2); 66.9 (CH2OCH2); 119.0 (C-3); 127.0, 128.5, 130.1
(ArCH); 125.6, 138.1, 147.3 (ArCqu); 152.5 (C-2); 159.6 (C-6.); 169.9 (C=O).
Anal. Calcd. for C22H29N3O2: C, 71.89; H, 7.96; N, 11.44; found: C, 71.75; H, 7.83;
N,11.29.
1-[4-methyl-6-(2-morpholin-4-yl-2-oxo-ethyl)-3-phenyl-pyridin-2-yl]-
pyrrolidine-2-carboxylic acid methyl ester 6f
(EtOAc/cyclohexane, 7:3); pale yellow oil; 1H NMR δ 1.67-1.83 (4H, m, 2 x CH2
proline); 2.06 (3H, s, p-CH3); 2.9 (2H, m, CH2-N); 3.55-3.68 (8H, m, O=CN(CH2)2
and CH2OCH2); 3.72 (3H, s, OCH3); 3.79 (2H, s, CH2); 4.80 (1H, m, H on C*); 6.57
(1H, s, H-3); 7.21-7.37 (5H, m, ArH).
2-(4-Methyl-6-morpholino-5-p-tolyl-pyridin-2-yl)-1-piperidin-1-yl-ethanone 6g
(EtOAc/cyclohexane, 7:3); cream needles from iPr2O; mp 90°C; IR (Nujol) νmax
1644 (C=O) cm-1; 1H NMR δ 1.42-1.65 (6H, m, CH2CH2CH2); 2.05 (3H, s, p-CH3);
2.39 (3H, s, CH3-tolyl); 2.84-2.98 (4H, m, CH2NCH2); 3.43-3.50 (4H, m,
CH2OCH2); 3.56-3.68 (4H, m, O=CN(CH2)2); 3.79 (2H, s, CH2); 6.85 (1H, s, H-3);
7.11-7.24 (4H, m, ArH); 13C NMR δ 20.6 (p-CH3); 21.3 (CH3-tolyl); 24.6, 25.6, 26.5
(CH2CH2CH2); 43.0 and 43.7 (O=C-N(CH2)2); 47.6 (CH2-C=O); 49.6 (CH2NCH2);
66.9 (CH2OCH2), 118.8 (C-3); 129.2, 129.9, (ArCH); 125.5, 134.9, 136.6, 147.4
(ArCqu); 152.0 (C-2); 159.6 (C-6); 168.9 (C=O). Anal. Calcd. for C24H31N3O2: C,
73.25; H, 7.94; N, 10.68; found: C, 73.17; H, 7.85; N,10.89.
2-[5-(4-Chlorophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-piperidin-1-yl-
ethanone 6h
(EtOAc/cyclohexane, 6:4); cream plates from iPr2O; mp 86°C; IR (Nujol) νmax 1620
(C=O) cm-1; 1H NMR δ 1.38-1.70 (6H, m, CH2CH2CH2); 2.04 (3H, s, p-CH3); 2.90-
3.00 (4H, m, CH2NCH2); 3.43-3.54 (4H, m, CH2OCH2); 3.53-3.68 (4H, m, O=C-
N(CH2)2); 3.79 (2H, s, CH2); 6.87 (1H, s, H-3); 7.23 and 7.40 (4H, 2 x d, AB
system, J=8.5 Hz, ArH); 13C NMR δ 20.9 (p-CH3); 25.0, 26.0, 26.9 (CH2CH2CH2);
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43.4 and 43.9 (O=C-N(CH2)2); 48.0 (CH2-C=O); 50.2 (CH2NCH2); 67.2
(CH2OCH2); 119.5 (C-3); 129.2, 131.9 (ArCH); 124.9, 133.3, 136.9, 147.7 (ArCqu);
153.1 (C-2); 160.0 (C-6); 169.1 (C=O). Anal Calcd. for C23H28ClN3O2: C, 66.74, H,
6.82, N, 10.15; found: C, 66.63; H, 6.77; N, 10.21.
2-[5-(4-Chlorophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-(4-methyl-
piperazin-1-yl)-ethanone 6i
(MeOH/EtOAc, 7:3); cream plates from iPr2O; mp 115°C; IR (Nujol) νmax 1630
(C=O) cm-1; 1H NMR δ 2.06 (3H, s, p-CH3); 2.31 (3H, s, CH3-N); 2.30-2.50 (4H, m,
(CH2)2NCH3); 2.93-3.00 (4H, m, CH2NCH2); 3.45-3.57 (4H, m, CH2OCH2); 3.65-
3.80 (4H, m, O=C-N(CH2)2); 3.81 (2H, s, CH2); 6.88 (1H, s, H-3); 7.25 and 7.41
(4H, 2 x d, AB system, J=8.4 Hz, ArH); 13C NMR δ 20.4 (p-CH3); 41.8 and 43.3
(H3C-N(CH2)2); 46.1 (H3C-N); 46.5 (CH2-C=O); 49.8 (CH2NCH2); 54.7 and 55.3
(O=CN(CH2)2); 66.8 (CH2OCH2); 119.2 (C-3); 128.8, 131.5 (ArCH); 124.6, 133.0,
136.4, 147.5 (ArCqu); 152.4 (C-2,); 159.6 (C-6); 169.0 (C=O). Anal. Calcd. for
C23H29ClN4O2: C, 66.46; H, 6.83; N, 13.08; found: C, 66.39; H, 6.81; N,13.09.
2-[5-(4-Bromophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-piperidin-1-yl-
ethanone 6j
(EtOAc/cyclohexane, 7:3); orange plates from iPr2O; mp 93°C; IR (Nujol) νmax 1633
(C=O) cm-1; 1H NMR (200 MHz,) δ 1.40-1.78 (6H, m, CH2CH2CH2), 2.06 (3H, s, p-
CH3), 2.92-3.00 (4H, m, CH2NCH2), 3.48-3.56 (4H, m, CH2OCH2); 3.58-3.71 (4H,
m, O=C-N(CH2)2); 3.81 (2H, s, CH2); 6.89 (1H, s, H-3) 7.20 and 7.56 (4H, 2 x d,
AB system, J=8.4 Hz, ArH); 13C NMR δ 20.5 (p-CH3); 24.6, 25.6, 26.6
(CH2CH2CH2); 43.0 and 43.6 (O=C-N(CH2)2); 47.6 (CH2-C=O); 49.8 (CH2NCH2);
66.9 (CH2OCH2); 119.2 (C-3); 121.5 (C-5);131.7 and 131.8 (ArCH) 124.5 and 137
(2 ArCqu) 147.3 (C-4); 152.8 (C-2); 159.5 (C-6); 168.8 (C=O). Anal. Calcd. for
C23H28BrN3O2: C, 60.26; H, 6.16; N, 9.17; found: C, 59.94; H, 6.15; N, 8.98.
2-[5-(4-Bromophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-(4-methyl-
piperazin-1-yl)-ethanone 6k
(MeOH/EtOAc, 7:3); ochre plates from iPr2O; mp 112°C; IR (Nujol) νmax 1650
(C=O) cm-1; 1H NMR δ 2.06 (3H, s, 3H, p-CH3); 2.32 (3H, s, N-CH3); 2.36-2.44
30
(4H, m, (CH2)2NCH3); 2.92-2.97 (4H, m, CH2NCH2); 3.47-3.52 (4H, m, CH2OCH2);
3.68-3.79 (4H, m, O=C-N(CH2)2); 3.81 (2H, s, CH2); 6.88 (1H, s, H-3); 7.19 and
7.57 (4H, 2 x d, AB system, J=8.1 Hz, ArH); 13C NMR δ 20.5 (p-CH3); 41.8 and
43.3 (H3C-N(CH2)2); 46.1 (H3C-N); 46.5 (CH2-C=O); 49.8 (CH2NCH2); 54.7 and
55.3 (O=C-N(CH2)2); 66.8 (CH2OCH2); 119.2 (C-3); 131.8 (ArCH); 121.1, 124.6,
136.9, 147.4 (ArCqu); 152.4 (C-2); 159.6 (C-6); 169.0 (C=O). Anal. Calcd. for
C23H29BrN4O2: C, 58.35, H, 6.17, N, 11.83; found: C, 58.50; H, 6.17; N, 11.71
4-{2-[5-(4-Bromophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-acetyl}-
piperazine-1-carboxylic acid ethyl ester 6l
(EtOAc/cyclohexane, 9:1); white crystals from iPr2O; mp 142°C; IR (Nujol) νmax
1632 (C=O), 1680 (N-C=OO) cm-1; 1H NMR δ 1.29 (3H, t, J=7 Hz, CH3-CH2); 2.07
(3H, s, p-CH3), 2.92-2.97 (4H, m, CH2NCH2); 3.40-3.60 (8H, m, CH2OCH2 and
(CH2)2NCOOEt); 3.64-3.77 (4H, m, O=C-N(CH2)2); 3.83 (2H, s, CH2); 4.17 (2H,
dd, J=7 Hz, CH2-CH3); 6.89 (1H, s, H-3); 7.19 and 7.58 (4H, 2 x d, AB system,
J=8.4 Hz, ArH); 13C NMR δ 14.7 (CH3-CH2); 20.5 (p-CH3); 41.7 (C2H5OCO-
N(CH2)2); 43.5 and 43.9 (O=C-N(CH2)2); 46.3 (CH2-C=O); 49.8 (CH2NCH2); 61.8
(CH2OC=O); 66.8 (CH2OCH2); 119.2 (C-3); 132.0 and 132.1 (ArCH); 121.2, 124.8,
136.7, 147.6 (ArCqu); 152.1 (C-2); 155.8 (COOC2H5); 160.0 (C-6); 169.2 (C=O).
Anal. Calcd. for C25H31BrN4O4: C, 56.59; H, 5.89; N, 10.57; found: C, 56.36; H,
5.72; N, 10.34.
2-[5-(4-Bromophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-morpholin-4-yl-
ethanone 6m
(EtOAc/cyclohexane, 6:4); white plates from iPr2O; mp 131°C; IR (Nujol) νmax 1650
(C=O) cm-1; 1H NMR δ 2.07 (s, 3H, CH3 on C-4); 2.95 (m 4H, CH2NCH2); 3.50 (m,
4H, CH2OCH2); 3.64-3.77 (m, 8H, O=C-N(CH2)2 and CH2OCH2); 3.81 (s,2H,CH2);
6.90 (s, 1H, H-meta); 7.20 and 7.58 (2xd, 4H, J=8.4, ArylH);13C NMR δ 20.5 (CH3
para) 42.3 and 43.2 (O=C-N(CH2)2); 47.0 (CH2-C=O); 49.8 (CH2NCH2 morph.);
66.8 (CH2OCH2), 66.9 (CH2OCH2);119.3 (C-3); 131.8 (Ar CH); 121.2, 124.8 (Ar
Cqu); 157.564 (C-2); 152.245 (C-6 linked to Morph.); 169.201 (C=O).
2-[5-(4-Bromophenyl)-4-methyl-6-morpholin-4-yl-pyridin-2-yl]-N,N-diethyl-4-
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acetamide 6n
(MeOH/EtOAc, 1:1); pale yellow-orange oil; 1H NMR δ 1.13-1.27 (m, 6H, 2 x CH3-
CH2); 2.06 (s, 3H, CH3); 2.94-2.98 (m 4H, CH2NCH2 morph); 3.39-3.62 (m, 8H,
CH2NCH2 diethyl and CH2OCH2); 3.77 (s,2H,CH2); 6.89 (s, 1H, H-meta); 7.20 and
7.57 (2xd, 4H, J=8.4, ArylH).
2-[5-(4-Bromophenyl)-4-methyl-6-piperazino-pyridin-2-yl]-1-(4-methyl-
piperazin-1-yl)-ethanone 6o
(MeOH/EtOAc, 1:1); ochre plates from iPr2O; mp 118°C; IR (Nujol) νmax 1635
(C=O) cm-1; 1H NMR δ 2.05 (s, 3H, CH3 in para), 2.26 (s, 3H, N-CH3 pip. in 6) 2.30
(s, 3H, N-CH3 amidic piperazine); 2.24-2.29 (m, 4H, (CH2)2NCH3 in 6); 2.33-2.415
(m, 4H, (CH2)2NCH3 amidic); 3.00-3.05 (m, 4H, (CH2)2N in 6); 3.66-3.77 (m, 4H,
O=C-N(CH2)2); 3.80 (s, 2H, CH2); 6.86 (s, 1H, H-meta); 7.18 and 7.56 (2xd, 4H,
J=8.4, ArylH); 13C NMR δ 20.6 (CH3 on C-4 para); 41.8 and 43.4 (H3C-N(CH2)2);
45.6 (CH3 linked to C-6) 46.1 (H3C-N- on amidic piperazine); 46.5 (CH2-C=O);
49.1 (CH2NCH2); 54.7 and 55.3 (O=C-N(CH2)2); 55.0 (CH2NCH2); 118.9 (C-3-
meta); 131.7-131.9 (Ar CH ); 121.0, 124.4, 137.1, 147.2 (Ar Cqu); 152.3 (C-2);
159.7 (C-6); 169.1 (C=O).
2-[5-(4-Fluorophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-piperidin-1-yl-
ethanone 6p
(EtOAc/cyclohexane, 7:3); pale yellow oil; IR (liquid film) νmax 1640 (C=O) cm-1;
1H NMR δ 1.42-1.63 (6H, m, CH2CH2CH2); 2.04 (3H, s, p-CH3); 2.95-2.99 (4H, m,
CH2NCH2); 3.45-3.51 (4H, m, CH2OCH2); 3.54-3.67 (4H, m, O=C-N(CH2)2); 3.79
(2H, s, CH2); 6.87 (1H, s, H-3); 7.10 and 7.29 (4H, 2 x d, AB system, J=8.8 Hz,
ArH); 13C NMR δ 20.4 (p-CH3); 24.5, 25.6, 26.5 (CH2CH2CH2); 42.9 and 43.5
(O=C-N-(CH2)2); 47.6 (CH2-C=O); 49.7 (CH2NCH2); 66.8 (CH2OCH2); 115.3 and
115.7 (ArCH. ortho to F, J=21.5 Hz); 119.0 (C-3); 124.7 (C-5); 131.6 and 131.8
(ArCH meta to F, J=7.7 Hz); 133.7 and 133.8 (ArCqu para to F, J=3 Hz); 147.4 (C-
4); 152.5 (C-2); 159.7 (C-6); 159.3 and 164.2 (C linked to F, JCF =247.0 Hz); 168.8
(C=O). Anal. Calcd. for C23H28FN3O2: C, 69.48; H, 7.10; N, 10.58; found: C, 69.39;
H, 7.03; N, 10.46.
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2-[5-(4-Fluorophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-(4-methyl-
piperazin-1-yl)-ethanone 6q
(MeOH/EtOAc, 7:3); cream plates from iPr2O; mp 50°C; IR (Nujol) νmax 1632
(C=O) cm-1; 1H NMR δ 2.04 (3H, s, p-CH3), 2.27 (3H, s, CH3-N); 2.30-2.43 (4H, m,
(CH2)2NCH3); 2.85-2.97 (4H, m, CH2NCH2); 3.35-3.47 (4H, m, CH2OCH2); 3.60-
3.75 (4H, m, O=C-N(CH2)2); 3.78 (2H, s, CH2); 6.87 (1H, s, H-3); 7.10 and 7.29
(4H, 2 x d, AB system J=8.8 Hz, ArH). 13C NMR δ 20.4 (p-CH3); 41.8 and 43.3
(H3C-N(CH2)2); 46.1 (H3C-N); 46.4 (CH2-C=O); 49.8 (CH2NCH2); 54.7 and 55.3
(O=C-N (CH2)2); 66.8 (CH2OCH2); 115.3 and 115.8 (ArCH. ortho to F, J=21.5);
119.1 (C-3); 124.8 (C-5); 131.6 and 131.8 (ArCH meta to F J=7.8); 133.7 and 133.8
(ArCqu para to F, J=2.9 Hz); 147.5 (C-4); 152.2 (C-2); 159.80 (C-6); 159.4 and
164.3 (C linked to F, JCF =247.0); 169.1 (C=O). Anal. Calcd. for C23H29FN4O2: C,
66.95; H, 7.09; N, 13.59; found: C, 66.75; H, 6.99; N, 13.51.
2-[5-(2,4-Dichlorophenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-(4-methyl-
piperazin-1-yl)-ethanone 6r
(MeOH/EtOAc, 7:3); yellow oil; IR (liquid film) νmax 1643 (C=O) cm-1; 1H NMR δ
2.00 (3H, s, p-CH3); 2.30 (3H, s, CH3-N); 2.32-2.40 (4H, m, (CH2)2NCH3); 2.95-
3.00 (4H, m, CH2NCH2); 3.47-3.55 (4H, m, CH2OCH2); 3.66-3.78 (4H, m, O=C-N
(CH2)2); 3.83 (2H, s, CH2); 6.90 (1H, s, H-3); 7.18 (1H, d, J=8.1 Hz, H-6’); 7.34
(1H, dd, J=8.1 Hz and J=2.2 Hz, H-5’), 7.53 (1H, d, J=2.2 Hz, H-3’); 13C NMR δ
19.6 (p-CH3); 41.8 and 43.5 (H3C-N(CH2)2); 46.0 (H3C-N); 46.4 (CH2-C=O); 49.73
(CH2NCH2); 54.7 and 55.2 (O=C-N(CH2)2); 66.8 (CH2OCH2); 118.9 (C-3); 127.5,
129.7, 132.8 (Ar CH); 122.9, 134.0, 135.1, 135.7, 148.5 (Ar Cqu); 153.3 (C-2);
159.7 (C-6); 169.0 (C=O). Anal. Calcd. for C23H28Cl2N4O2: C, 59.72; H, 6.11; N,
12.12; found: C, 59.57; H, 6.04; N 11.96.
2-[5-(4-Methoxyphenyl)-4-methyl-6-morpholino-pyridin-2-yl]-1-piperidin-1-yl-
ethanone 6s
(EtOAc/cyclohexane, 7:3); pale yellow-orange oil; IR (liquid film) νmax 1625 (C=O)
cm-1; 1H NMR δ 1.40-1.70 (m, 6H, CH2CH2CH2); 2.05 (s, 3H, CH3-para); 2.90-3.00
(m, 4H, CH2NCH2); 3.43-3.53 (m, 4H, CH2OCH2); 3.50-3.67 (m, 4H, O=C-
N(CH2)2); 3.78 (s, 2H, CH2); 3.85 (s, 3H, OCH3); 6,85 (s, 1H, H-3); 6.94 and 7.20 (2
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x d, 4H, aromatic AB system, J=8.7,arom H). 13C NMR δ 21.6 (CH3); 25.0, 26.0,
26.9 (CH2CH2CH2); 43.4, 44.0 (CH2NCH2); 48.1 (CH2-C=O); 50.0 (CH2NCH2
linked to C=O); 55.7 (OCH3); 67.4 (CH2OCH2); 114.3, 131.5 (Ar CH); 119.3 (C-3);
125.6, 130.4, 147.9 (Ar Cqu); 152.3 (C-2, N=C-CH2);158.9 (Cqu OCH3 linked);
160.2 (C-6); 169.4 (C=O).
2-(4,5-Dimethyl-6-morpholino-pyridin-2-yl)-1-piperidin-1-yl-ethanone 6t
(EtOAc/cyclohexane, 7:3); white needles from iPr2O; mp 81°C; IR (Nujol) νmax
1630 (C=O) cm-1; 1H NMR δ 1.30-1.65 (6H, m, CH2CH2CH2); 2.17 (3H, s, m-CH3);
2.23 (3H, s, p-CH3); 2.98-3.10 (4H, m, CH2NCH2); 3.50-3.68 (4H, m, O=C-
N(CH2)2); 3.78 (2H, s, CH2); 3.80-3.87 (4H, m, CH2OCH2); 6.87 (1H, s, H-3); 13C
NMR δ 14.2 (m-CH3); 20.2 (p-CH3); 24.9, 25.9, 26.9 (CH2CH2CH2); 43.3 and 44.1
(O=C-N-(CH2)2); 47.9 (CH2-C=O); 51.1 (CH2NCH2); 67.6 (CH2OCH2); 120.1 (C-3);
121.7 (C-5); 148.4 (C-4); 151.1 (C-2); 161.4 (C-6); 169.3 (C=O). Anal. Calcd. for
C18H27N3O2: C, 68.09; H, 8.58; N, 13.24; found: C, 68.36; H, 8.65; N 13.19
2-(4,5-dimethyl-6-piperidino-pyridin-2-yl)-1-piperidin-1-yl-ethanone 7a
white needles from iPr2O; mp 72°C; IR (Nujol) νmax 1630 (C=O) cm-1; 1H NMR δ
1.30-1.80 (12H, m, 2 x CH2CH2CH2); 2.15 (3H, s, m-CH3); 2.19 (3H, s, p-CH3);
2.92-3.06 (4H, m, CH2NCH2); 3.50-3.68 (4H, m, O=C-N (CH2)2); 3.76 (2H, s, CH2);
6.80 (1H, s, 1H, H-3); 13C NMR δ 14.3 (m-CH3); 20.3 (p-CH3); 25.0, 25.1, 26.0,
26.7, 26.8 (CH2 of piperidines); 43.3, 44.4 (O=C-N-(CH2)2); 47.9 (CH2-C=O); 52.0
(CH2NCH2); 119.3 (C-3); 121.9 (C-5); 148.0 (C-4); 150.8 (C-2); 162.9 (C-6); 169.6
(C=O). Anal. Calcd. for C19H29N3O: C, 72.33, H, 9.27, N, 13.33; found: C, 72.28; H,
9.19; N, 13.25.
2-(4,5-Dimethyl-6-morpholino-pyridin-2-yl)-1-(4-methyl-piperazin-1-yl)-
ethanone 6u
(MeOH/EtOAc, 7:3); pale yellow oil; IR (liquid film) νmax 1644 (C=O) cm-1; 1H
NMR δ 2.18 (3H, s, m-CH3); 2.23 (3H, s, p-CH3) 2.31 (3H, s, CH3-N); 2.33-2.43
(4H, m, (CH2)2NCH3); 3.02-3.10 (4H, m, CH2NCH2); 3.62-3.76 (4H, m, O=C-
N(CH2)2); 3.77 (2H, s, CH2); 3.82-3.88 (4H, m, CH2OCH2); 6.85 (1H, s, H-3); 13C
NMR δ 14.0 (m-CH3); 20.0 (p-CH3); 41.7 and 43.5 ((CH2)2NCH3); 46.1 (N-CH3);
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46.3 (CH2C=O); 50.8 (CH2NCH2); 54.7 and 55.3 (O=C-N(CH2)2); 67.2 (CH2OCH2);
119.9 (C-3); 121.6 (C-5); 148.3 (C-4); 150.4 (C-2); 161.1 (C-6); 169.3 (C=O). Anal.
Calcd. for C18H28N4O2: C, 65.02, H, 8.48, N, 16.86; found: C, 64.83; H, 8.42; N
16.68.
2-[4,5-dimethyl-6-(4-methyl-piperazin-1-yl)-pyridin-2-yl]-1-(4-methyl-
piperazin-1-yl)-ethanone 7b
pale yellow oil; IR (liquid film) νmax 1643 (C=O) cm-1; 1H NMR δ 2.15 (3H, s, m-
CH3); 2.21 (3H, s, p-CH3); 2.27 (3H, s, N-CH3); 2.33-2.38 (4H, m, (CH2)2NCH3);
2.44 (3H, s, N-CH3); 2.64-2.74 (4H, m, (CH2)2NCH3); 3.12-3.22 (4H, m,
CH2NCH2); 3.61-3.73 (4H, m, O=C-N-(CH2)2); 3.76 (2H, s, CH2); 6.83 (1H, s, H-3);
13C NMR δ 14.1 (m-CH3); 20.0 (p-CH3); 41.7 and 43.6 ((CH2)2NCH3); 46.0 (N-
CH3); 46.2 (N-CH3); 46.4 (CH2C=O); 50.0 (CH2NCH2); 54.7 and 55.3 (O=C-
N(CH2)2 and CH2NCH2); 119.5 (C-3); 121.5 (C-5); 148.1 (C-4); 150.2 (C-2); 161.1
(C-6); 169.4 (C=O). Anal. Calcd. for C19H31N5O: C, 66.04, H, 9.05, N, 20.28; found:
C, 66.31; H, 9.13; N 20.07.
2-(4-Methyl-5-methylsulfanylmethyl-6-morpholino-pyridin-2-yl)-1-(4-methyl-
piperazin-1-yl)-ethanone 6v
(MeOH/EtOAc, 7:3); chestnut plates from iPr2O; mp 72°C; IR (Nujol) νmax 1643
(C=O) cm-1; 1H NMR δ 2.11 (3H, s, CH3S); 2.25 (3H, s, p-CH3); 2.20-2.34 (4H, m,
(CH2)2NCH3); 2.37 (3H, s, N-CH3); 3.08-3.14 (4H, m, CH2NCH2); 3.40-3.72 (4H,
m, O=C-N(CH2)2); 3.75 (2H, s, CH2S); 3.77 (2H, s, CH2CO); 3.80-3.86 (4H, m,
CH2OCH2); 6.87 (1H, s, H-3); 13C NMR δ 16.3 (CH3S); 19.2 (p-CH3); 31.3 (CH2S);
41.8 and 43.5 ((CH2)2NCH3); 46.0 (NCH3); 46.3 (CH2C=O); 51.8 (CH2NCH2); 54.7
and 55.2 (O=C-N(CH2)2); 67.3 (CH2OCH2); 121.3 (C-3); 123.0 (C-5); 149.5 (C-4);
152.2 (C-2); 161.9 (C-6); 168.9 (C=O). Anal. Calcd. for C19H30N4O2S: C, 60.28; H,
7.99; N, 14.81; found: C, 60.35; H, 8.13; N, 14.76.
2-[4-Methyl-6-(4-methyl-piperazin-1-yl)-5-methylsulfanylmethyl-pyridin-2-yl]-
1-(4-methyl-piperazin-1-yl)-ethanone 7c
yellow oil; IR (liquid film) νmax 1644 (C=O) cm-1; 1H NMR δ 2.13 (3H, s, CH3S);
2.27 (3H, s, p-CH3); 2.30-2.42 (4H, m, (CH2)2NCH3); 2.39 (3H, s, N-CH3); 2.41
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(3H, s, N-CH3); 2.58-2.67 (4H, m, (CH2)2NCH3); 3.18-3.24 (4H, m, CH2NCH2);
3.58-3.72 (4H, m, O=C-N(CH2)2); 3.77 (2H, s, CH2S); 3.78 (2H, s, CH2CO); 6.89
(1H, s, H-3); 13C NMR δ 16.3 (CH3S); 19.3 (p-CH3); 31.3 (CH2S); 41.8 and 43.6
(CH2)2NCH3); 46.1 (N-CH3); 46.3 (N-CH3); 46.4 (CH2C=O); 51.3 (CH2NCH2); 54.7
and 55.0 (O=C-N (CH2)2); 55.2 and 55.5 ((CH2)2NCH3); 121.0 (C-3); 122.9 (C-5);
149.3 (C-4); 152.0 (C-2); 161.9 (C-6); 169.1 (C=O). Anal. Calcd. for C20H33N5OS:
C, 61.34; H, 8.50; N, 17.90; found: C, 61.39; H, 8.65; N,17.81.
2-[3'-(4-Methoxyphenyl)-4'-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridin-yl-6'-
yl]-1-piperidin-1-yl-ethanone 7d
(EtOAc/cyclohexane, 7:3); pale yellow-orange oil; IR (liquid film) νmax 1620 (C=O)
cm-1; 1H NMR δ 1.25-1.62 (m, 12H, 2 x CH2CH2CH2); 2.03 (s, 3H, CH3-para); 2.89-
2.94 (m, 4H, CH2NCH2); 3.56-3.67 (m, 4H, O=C-N(CH2)2); 3.78 (s, 2H, CH2); 3.85
(s, 3H, OCH3); 6.79 (s, 1H, H-3); 6.91 and 7.21 (2 x d, 4H, aromatic AB system,
J=8.7,arom H). 13C NMR δ 21.1 (CH3); 25.1, 26.1, 26.3, 26.9 (2 x CH2CH2CH2);
43.4, 44.3 (CH2NCH2); 48.1 (CH2-C=O); 50.9 (CH2NCH2 linked to C=O); 55.7
(OCH3); 114.1, 131.6 (Ar CH); 118.5 (C-3); 125.8, 131.1, 147.5 (Ar Cqu); 152.1
(C-2, N=C-CH2);158.7 (Cqu OCH3 linked); 161.6 (C-6); 169.6 (C=O).
2-[5-(1,5-dimethyl-hex-4-enyl)-4-methyl-6-morpholin-4-yl-pyridin-2-yl]-1-(4-
methyl-piperazin-1-yl)-ethanone 6w
(EtOAc/cyclohexane, 7:3); pale yellow oil; 1H NMR δ 1.31 (d, 3H, J=7.0, CH3 on
CH); 2.26 (s, 3H, CH3-para); 2.22-2.36 (4H, m, (CH2)2NCH3); 2.33 (s, 3H, CH3
vinyl); 2.41 (s, 3H, CH3 vinyl); 2.37 (s, 3H, N-CH3); 3.02-3.09 (m, 4H, CH2NCH2);
3.40-3.62 (m, 4H, O=C-N(CH2)2); 3.64-3.73 (m, 4H, CH2OCH2); 3.75 (s, 2H,
CH2CO); 5.11 (m, 1H, CH vinyl); 6.88 (s; 1H, H-3);
2CH2 fall between 1.3 and 2.2 ; H on C* should fall between 2 and 4 based on
enamine spectra. 
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1. Background
Since several years our group collaborate with the research group of Prof. Alberto
Corsini at “Dipartimento di Scienze Farmacologiche” providing novel organic small
molecules for a blind screening project. Aim of this study is to isolate new
molecules potentially active for patologies derived from abnormal cellular
proliferation, as atherosclerosis and cancer. The inhibitory activity of the considered
organic molecules is evaluated as their ability to inhibit rat's aortha smooth
muscular cells proliferation. Migration and proliferation of smooth muscle cells in
the arterial wall are early prominent features of atherogenesis and represent major
mechanisms involved in vascular occlusion in both atherosclerosis and restenosis
after angioplasty26. 
A preliminary screening showed certain actvity for some of our early sinthetized 2-
piridinacetamides, inhibiting SMC proliferation with IC50's between 50 and 100 µM,
values not enthusiasting but enough to induce us to deeper explore an eventual role
of those novel amides in interfering with the cellular activities. Our next task was
then to identify a potential target, thus we performed an exahustive bibliography
search using the SciFinder database. Most molecules containing in their structures
the 2-pyridinacetamidic nucleus resulted to be tirosin kinase receptors inhibitors27.
Indeed, an arterial injury leads to extensive platelet activation, adhesion, followed
by platelet aggregation and secretion28. Platelet secretion results in the local release
of intracellular granuli constituents, including platelet-derived growth factor PDGF
, as well as epidermal growth factor EGF29; these factors have been identified as
potent endogenous smooth muscle cell mitogens26b. PDGF-BB is also one of the
most potent chemoattractive agents26b. Furthermore, the epidermal growth factor
receptor (EGFRK) is a rational target for antitumor strategies. EGFRK signaling
causes increased proliferation, decreased apoptosis, and enhanced tumor cell
26a) J.H. Ip et al., J. Am. Coll. Cardiol., 1990, 15, 1667-1687.
    b) R. Ross, Nature, 1993, 362, 801-809. 
    c) J.M. Isner et al., Trends Cardiovasc. Med., 1994, 4, 213-221.
27W.E. Barth and M.J. Luzzio, Pfizer, PCT C07D 401/14, 7 June 2001 
28a) J.H. Ip et al., J. Am. Coll. Cardiol., 1990, 15, 1667-1687.
    b) R. Ross, Nature, 1993, 362, 801-809. 
    c)H. Le Breton et al., J. Am. Coll. Cardiol., 1996, 28, 1643-1651. 
29a)Y. Oka and D.N. Orth, J. Clin. Invest., 1983, 72, 249-259. 
    b) R.K. Assoian et al., Nature, 1984, 309, 804-806.
    c)R. Ross, Nature, 1993, 362, 801-809. 
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motility and neo-angiogenesis. 
2. Receptor Tyrosine Kinases
Receptors tyrosine kinases (RTK) are trans membrane glycoproteins activated by
the binding of peptidic ligands, transducing the extracellular signal to the cytoplasm
by phosforylating tyrosine residues on the receptors themselves
(autophosphorylation) and on downstream signaling proteins, thus leading to cell
proliferation, differentiation, migration or metabolic changes30. The RTK family
includes receptor for insulin and growth factors like epidermal growth factor,
fibroblast growth factor, platelet-derived growth factor, vascular endothelial growth
factor and nerve growth factor. The specific reaction catalyzed by phosphoriled
RTK is the transfer of the γ phosphate from ATP to the hydroxyl group of a
tyrosine in a protein substrate. Due to their role in cellular proliferation RTKs are
actually one of the most important target for new anti-proliferative therapies.
Several groups all over the world are involved in structural and functional
classification of Tyrosine Kinase receptors (RTK), as in the design and synthesis of
selective inhibitors31. Crystal structures of the tyrosine kinase domains from several
RTKs have been reported32, the first of which was cyclic AMP-dependent protein
kinase (PKA)33. One of the best characterized catalytic domain is that of insulin
receptor34, represented in Figure 1. The overall architecture of the tyrosine kinase
domain consist in an amino-terminal lobe comprising a five-stranded β sheet and
one α helix, and a larger carboxy-terminal lobe that is mainly α-helical. ATP binds
in the cleft between the two lobes, and the tyrosine-containing peptide substrate
binds to the carboxy-terminal lobe. Several residues are highly conserved in all
protein kinases, including several glycines in the nucleotide-binding loop, a lysine
in β-strand 3, a glutamic acid in α-helix C, an aspartic acid and asparagine in the
catalytic loop, and a DFG motif in the beginning of the activation loop13. RTKs
could assume two conformations, an inactive form or an active form. In the non-
signaling state, most RTKs possess low basal kinase activity that increase
substantially upon growth factor binding (activation). This results from receptor
30 J. Schlessinger and A. Ullrich, 1992, 9, 383-391.
31 a) L. Sun et al., Bioorganic & Medicinal Chemistry Letters, 2002, 12, 2153-2157.
b) W. A. Denny et al., J. Med. Chem., 2000, 42, 2373-2382.
32 Taylor SS, Radzio-Andzelm E. 1994. Structure 2:345 55
33 Knighton DR, Zheng J, Ten Eyck LF, Ashford VA, Xuong N, et al. 1991. Science 253:407 14
34 S.R. Hubbard, EMBO J., 1997, 16, 5572-81.
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oligomerization and subsequent transphosphorylation of tyrosine residues within a
partner kinase domain: initial phosphotyrosine modification of the activation loop
generates optimal catalytic activity and subsequent rapid phosphorylation at
substrate docking sites elsewhere on the receptor intracellular domain. In the RTKs
for which crystal structures of both unphosphorylated and phosphorylated versions
of the kinase domain are available it's evident that phosphorilation in the activation
loop causes a large structural reorganization that relieves steric and chemical
restraints on the catalytic active site35. An exception to this are RTKs of the EGFRK
family that do not require this initial phosphorylation of of kinase domain residues
for full catalytic competency and such unique feature could partially explain why
EGFRK family members are frequently involved in abnormal cellular proliferation.
Due to unexpected results in anti proliferation activity of some of the 2-
pyridineacetamides reported in this dissertation, we will consider more closely
35 R. Hubbard and J. H. Till, Annu. Rev. Biochem., 2000, 69, 373-98.
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Figure1: cartoon diagram of the tyrosine kinase domain of theinsulin
receptor. The alpha helices are shown in purple, beta strands in
yellow. 
Nucleotide 
binding loop
Catalitic loop
Activation Loop
some TKR strongly implicated in angiogenesis associated with solid tumors, the
platelet derived growth factor receptor (PDGFRK), the vascular endothelial growth
factor receptor (VEGFRK) and the epidermal growth factor receptor (EGFRK).
Figure 2 shows the main paths, common for the considered RTKs, for signal
transduction: the interaction with specific ligands promotes receptor
oligomerization then autophosphorylation of tyrosine residues thus generating
docking sites for mediatory molecules responsible of transferring the message to the
nucleus.
The platelet-derived growth factor (PDGF) plays a vital role as a regulator of cell
growth36. Binding of PDGF to its trans membrane receptor leads to activation of its
36 a) L. Claesson-Welsh, Cytokines, 1993, 5, 31-43.
b) W. Meyer-Ingold, W. Eichner, Cell. Biol. Int., 1995, 19, 389-398.
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Figure 2: receptors tyrosin kinase signal transduction paths
Figure 2
intrinsic tyrosine kinase and autophosphorylation of the intracellular part of the
receptor. The autophosphorylated tyrosine residues mediate interactions with
downstream signal transduction molecules and thereby initiate different signaling
pathways, leading to activation of the GTP-binding protein Ras37 involving the
adaptor molecule GRB2. It has also been reported that ligand stimulation of the
PDGFRK beta leads to autophosphorylation of tyrosine residues, which is known to
mediate interactions with several SH2 domain-containing signaling molecules, such
as Shc38, mediating cellular activity.
Vascular endothelial growth factor (VEGF) is a dimeric glycoprotein which induces
angiogenesis through binding to VEGF-receptor-2 tyrosine kinase (VEGFRK) or
KDR (kinase insert domain-containing receptor) on the surface of endothelial cells.
According to sequence homology studies, VEGFRK is composed of an extracellular
ligand-binding region, a short membrane-spanning sequence, and an intracellular
region containing a putative tyrosine kinase domain39. On the basis of studies with
similar receptors of this type, VEGFRK is hypothesized to undergo dimerization
upon binding to VEGF, resulting in its activation. Upon activation, the receptor is
thought to initiate a cascade of phosphorylation which eventually leads to
vascularization40. Therefore, VEGFRK is recognized as the target for the
development of therapeutic drugs against angiogenesis.The crystal structure of
VEGFRK has been resolved41, providing a useful tool for drug discovery and
design.
EGFRK, also called HER and ErbB, belongs to the ErbB family of trans membrane
tyrosine kinase growth factor receptors. In addition to EGFRK, this family includes
ErbB2 (Neu, HER2), ErbB3 (HER3), and ErbB4 (HER4).Activities of EGFRK are
mediated by several signal transduction pathways. The best characterized of these is
the Ras/Raf/ERK pathway. On ligand binding and receptor activation, tyrosine
residues in the C-terminal region of EGFRK become phosphorylated and bind
various adaptor and signaling molecules. In the Ras/Raf/ERK pathway, the binding
of Grb2 recruits son-of-sevenless (SOS) to the membrane, which in turn activates
Ras and Raf. Activation of ERK leads to gene transcription resulting principally in
37 A.K. Arvidsson et al., Mol. Cell. Biol., 1994, 14, 6715-6726.
38 K. Yokote et al., J. Biol. Chem., 1994,269,15337-43
39 K. A. Thomas, J. Biol. Chem., 1996, 271, 603-606.
40 A. Ullrich and J. Schlessinger, Cell, 1990, 61, 203-212.
41 Michele A McTigue et. al., Structure, 1999, 7, 319-330.
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cell growth and proliferation (as well as other activities depending on the cell's
tissue of origin and differentiation). The binding of ligands by EGFRK can activate
other signaling pathways, such as the PI3K/PKB, PLC-³ /PKC, and MEKK/JNK
pathways, leading to various other cell activities.
Recent attention has focused on the epidermal growth factor receptor (EGFRK)
system because of the observation that deregulation of this receptor system is a
significant factor in the genesis or progression of several human cancers, including
those of the brain, lung, breast, ovary, pancreas, and prostate. 
Figure 3
Figure 3: EGFRK inhibitors currently in clinical trials
Few inhibitors of EGFRK are currently in clinical trial; promising drugs are
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anilinoquinazoline derivatives such OSI-774 (Tarceva)42 and ZD-1839 (Iressa)43,
both currently in Phase III clinical trial, and EKB-569. OSI-774 (Tarceva),
developed by OSI Pharmaceuticals/Genentech, like ZD-1839, is a highly specific,
orally active, and reversible inhibitor of EGFRK tyrosine kinase44. In clinical trials,
OSI-774 has shown anti tumor activity when given alone against non-small cell
lung carcinoma, ovarian cancer, and head and neck cancer. OSI-774 is now being
tested in phase III trials against non-small cell lung cancer and pancreatic cancer.
EKB-569 is instead an irreversible inhibitor of EGFRK, that might have the benefit
of eliminating all EGFRK kinase activity, which then can only be regenerated by
new synthesis of EGFRK by the cell. However, the advantage of this over reversible
inhibitors needs to be evaluated; actually EKB-569 is in Phase I clinical trial. As
shown in Figure 4, the peculiar aspect of irreversible inhibitors45 is the presence of a
Michael acceptor functional group at the C-6 or C-7 position, that form a covalent
linkage with the sulfhydryl group of the Cys 773 of EGFRK.
42 A. J. Barker et al., Bioorg. Med. Chem. Lett., 2001, 11, 1911.
43 M. Hidalgo et al., J. Clin. Oncol., 2001, 19, 3267.
44 M. Ranson et al., J. Clin. Oncol.,  2002, 20, 2240-2250.
45 H. Tsou et al., J. Med. Chem., 2001, 44, 2719-2734.
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Figure 4
As we can understand from what stated above targeting TK receptor in abnormal
cellular proliferation deseases is shown to be a promising therapy, but the relative
lack in selective inhibitors joint with recent advances made by biochemists in
describing the structures of catalitic domains and pathways involved in signal
transduction set the basis for a real need for identifying new structures with tyrosin
kinase receptors inhibitory activity.
45
Figure 4: proposed binding mode for EKB-569 derivative; distances
between Cys773 and the Michael acceptor group suggest the
possibility of a covalent linkage.
3. Pharmacological Results
We discuss now the ability of amido derivatives of 2-pyridinacetic acid 6 described
in Chapter 1 to inhibit rat's aorta smooth muscular cells proliferation.
Effect of 2-pyridinacetamides 6 on SMC proliferation
Smooth muscle cells were cultured according to Ross26 from intimal medial layers
of aorta of male Sprague Dawley rats (200 250 g). Cells were grown in monolayers
at 37°C in a humidified atmosphere of 5% CO2 in MEM supplemented with 10%
(v:v) fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 20 mM buffer
tricine and 1% v:v non-essential amino acid solution46. The medium was changed
every third day. Cells were used between the fourth and tenth passage. Smooth
muscle cells were identified for growth behaviour, morphology and using
monoclonal antibody specific for α -actin, the actin isoform typical of smooth
muscle cells. The cells grew out of explants after 12-16 days, piled up after
confluency and contained numerous myofilaments and dense bodies, as observed
by transmission electron microscopy. 
Myocytes were seeded at a density of 2x105 per 35 mm dish, and incubated with
MEM supplemented with 10% fetal calf serum47. 24 h later, the medium was
changed to one containing 0.4% fetal calf serum to stop cell growth and the cultures
incubated for 72 h. At this time (time 0), the medium was replaced with one
containing 10% fetal calf serum in the presence or absence of known concentrations
of the tested compounds and the incubations were continued for further 72 h at
37°C. At time 0, just before the addition of the substances to be tested, three petri
dishes were used for cell counting. Cell proliferation was evaluated by cell count
after trypsinization of the monolayers using a Coulter Counter model ZM. Smooth
muscle cell doubling time was computed according to Elmore and Swift48.
Results obtained by tests on 2-pyridinacetamides 6 are collected in table 1. Such
data show that many of the evaluated 2-pyridinacetamides 6 are able to inhibit SMC
proliferation with IC50 ranging from 100 µM to 3.5 µM when the mythogenicstimula
is given by FCS. Inside tested molecules, those resulted more active are amides 6
where R1 = p-Br-C6H4 and NR2 = N-methylpiperazine or morpholine, showing
46 A. Corsini et al, Atherosclerosis, 1993, 101, 117-125. 
47 A. Corsini et al, Arterioscler. Thromb. Vasc. Biol., 1995, 15, 420-428.
48 E. Elmore and M. Swift, J. Cell Physiol., 1976, 87, 229-234.
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respectively IC50 values of 5 and 3.5 µM.
Table 1
Comp R1 NR2 IC50 
( µM )
6a C6H5 piperidine NE
6b C6H5 N-methylpiperazine >100
6d C6H5 morpholine 46.65
6e C6H5 diethylamine 23.22
6s pCH3O-C6H4 piperidine 22.5
6g pCH3-C6H4 piperidine NE
6h pCl-C6H4 piperidine 35.93
6i pCl-C6H4 N-methylpiperazine 16
6j pBr-C6H4 piperidine 16
6k pBr-C6H4 N-methylpiperazine 5
6l pBr-C6H4 N-
carbethoxypiperazine 43
6m pBr-C6H4 morpholine 3.5
6p pF-C6H4 piperidine NE
6q pF-C6H4 N-methylpiperazine >50
6r 2,4 diCl-C6H4 N-methylpiperazine 13
6t CH3 piperidine NE
6u CH3 N-methylpiperazine NE
6v CH3SCH2 N-methylpiperazine NE
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Antiproliferative Activity, 
here reported in terms of 
IC50 , has been evaluated 
on rat’s aorta muscular 
smooth cells stimulated 
with FCS 10%
Effect of 2-pyridinacetamides 6 on doubling time of SMC
Doubling time, the time that cells need to duplicate, is another important parameter
for evaluating the antiproliferative effect, because it's known that this value
increases in a concentration dependent manner with either more potent and less
potent compounds. Doubling time is calculated with the following formula:
 (log 2) x (time range in hours) / log(final n° of cells) – log( initial n° of cells)
Experiments conducted on rat's SMC show that all active 2-pyridinacetamides are
able to increase the doubling time in a concentration dependent manner .
Experiments with PDGF and EGF as mithogenic stimulus
In order to assess if the activity of valuated 2-pyridinacetamides was somehow
selective on tyrosine kinase receptors PDGFRK and/or EGFRK a new set of
experiments where done. It's known that SCF mithogenic stimulus is not selective
for any particular target, and for this reason following experiments where done
using PDGF-BB or EGF as mitogenic stimulus. Rat's aorta SMC used for this study
express both receptors for the considered growht factors and for this reason are
reliable for our screening.
Synchronization of smooth muscle cells to the G 0/G1 interphase of the cell cycle
was accomplished by incubating logarithmically growing cultures (3x10-5
myocytes/petri dish) for 5 days in a medium containing 0.4% fetal calf serum.
Quiescent cells were then incubated for 20 h in a fresh medium containing 10%
fetal calf serum in the presence or absence of testing compounds. When PDGF-BB
was investigated, quiescence medium was replaced at the fourth day with one
containing 1% plasma-derived bovine serum. After 24 h, mitogenic stimuli were
added directly to the medium in the presence or absence of testing compounds. A
medium containing 0.1% bovine serum albumin was utilized when EGF was
employed as mitogenic stimulus. After 20 h, DNA synthew 3 x sis was estimated by
nuclear incorporation of [3H]thymidine, incubated with the cells (2 µCi/ml medium)
for 2 h according to Corsini et al.49 and radioactivity was measured with Aquasol
scintillation cocktail. 
At the moment such experiments were conducted only on pyridinacetamides where
R1= p-BrPhenyl and NR2 = piperidine or morpholine, but soon will be extended to
49 A. Corsini et al., J. Cardiovasc. Pharmacol., 1996, 28, 687-694.
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the whole series. Results (IC50 µM ) are summarized in Table 2.
Table 2
R1 NR2 FCS PDGF EGF 
pBr-C6H4 piperidine 16 7.18 1.5
pBr-C6H4 morpholine 3.5 1.8 0.7
As we can notice from data reported in Table 2 the tested compounds are 2 folds
more potent on cell lines stimulated to proliferation with PDGF-BB and about 10
folds more potent when EGF is used, compared to the results obtained on cells
stimulated with FCS. This results could confirm that examined 2-pyridinacetamides
act with a mechanism through receptors Tyrosine Kinase, and seems selective
toward EGFRK.
49
Graph 1: Pharmacological results for compound 6m
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Graph 2:Pharmacological results for compound 6j
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Graph 3:Pharmacological results for compound 6k
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1. Structure Activity Relationships
The first series of pyridineacetamides submitted to pharmacological screening was
formed by compounds 6a, 6b, 6s, 6g and 6h represented in Table 1
Table 1
Compound 6b resulted a modes inhibitor of rat's SMC, while the piperidinic amide
6a was totally inactive.However certain substituents at the para position of the
phenyl ring at C-5, namely the methoxy group or chlorine atom, are able to confer
to piperidinic amides 6s and 6h a certain antiproliferative activity, with IC50
respectively of 22 and 36 µM; compound 6g p-tolyl substituted was inactive.
Analyzing those results we retained obvious that the nucleus 2-pyridinacetamido
could represent a potential pharmacophore moiety if opportunely substituted, and
that R1 and NR2 were critical for activity. However, at the moment we discovered
such potentiality we had no idea about the potential mechanism of action.
We decided than to use classical QSAR techniques in order to help us choosing the
right substitutions for improoving compound 6 pharmacological properties.
Our first task was to valuate the need of an aromatic substituent at the C-5 position,
synthesizing a series of amides preneting an aliphatic or ethero aliphatic chain at C-
5, namely compounds 6t-w reported below.
Table 2
No 5-aliphatic substituted pyridine was found to ihnibit SMC proliferation, giving
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CH3
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R1
O
NR2
O
6a   C6H5                     piperidine                           NE
6b   C6H5                     N-methylpiperazine           101
6s    pCH3O-C6H4          piperidine                            22
6g    pCH3-C6H4              piperidine                           NE
6h   pCl-C6H4                    piperidine                           36
N° NR2R
1 IC50
N
CH3
N
R1
O
NR2
O
6t    CH3                     piperidine                           NE
6u   CH3                     N-methylpiperazine           NE
6v    CH3SCH2               N-methylpiperazine           NE
6w                                         N-methylpiperazine           NE
N° NR2
CH3
H3C
CH3
R1 IC50
us a confirmation that the aromatic substituent at C-5 is essential for activity.
We decided than to investigate the influence of the substitution on the phenyl ring,
keeping constant the NR2 moiety.
The para-methyl substituent didn't play any role in pharmacological activity,
however p-methoxy and p-chlorine did. Because of the positive effect that halogens
play on the synthetic route to achive final amides and commercial avaylability of
aldehyde precursors our choice was to evaluate the effect of fluorine and bromine
atoms. Results, compared to those obatained for 6h, are summarized in Table 3.
Table 3
Pharmacological results evidenced increasing activity proportionally to the steric
hindrance and lipophily of the halogen, in fact fluorine does not contribute to
pharmacological activity, while bromine halves IC50 values.
Summarizing R1 should be a substituted arylic group, and the substituent on the
phenyl ring influences the potency in the order:
H < pF < pCl < pCH3O < pBr
Our efforts were than concentrated on investigating the role of the NR2 moiety.
Preliminary results showed that compound 6a (R1 = Ph, NR2 = piperidine) was
totally inactive, while compound 6b (R1 = Ph, NR2 = N-methylpiperazine) gave a
modest activity. In order to better evaluate the effect of the amido substituent
without further influence we kept as reference compound the pyridine where R1 =
Ph. Synthesized products and pharmacological results are collected in Table 4.
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CH3
N
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O
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O
6j    4-BrPh                piperidine                             16
6p   4-F-Ph                 piperidine                            NE
6r   4-Cl-Ph                    piperidine                             36
N° NR2R
1 IC50
Table 4
Values reported in Table 4 underline the importance of the amido substituent for
antiproliferative activity, as it's contribution to the potency increases in the order:
piperidine < N-methylpiperazine < morpholine < diethylamine
To confirm those results we repeated this study by variating NR2 on compounds
bearing R1 = pBrPh, wich resulted the aryl substituent apporting the greater
contribution to pharmacological potency, and by variating R1 on compounds
bearing N-methylpiperazine as amidic substitution. Further evaluations involved a
2,4 dichlorophenil group as R1 and N-carbethoxypiperazine as amine. Results are
summarized in Table 4 and Graph 1.
Table 4
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6j     pBr Ph           piperidine                                 16
6k    pBr Ph           N-methylpiperazine                   5
6l     pBr Ph              N-carbethoxypiperazine           43       
6m   pBr Ph           morpholine                                3.5
6b    Ph                  N-methylpiperazine                101
6i     pCl Ph           N-methylpiperazine                  16
6q    pF-Ph            N-methylpiperazine                  55
6r    2,4diClPh      N-methylpiperazine                  13
N° NR2R
1 IC50
N
CH3
N
R1
O
NR2
O
N° NR2R
1 IC50
6a    Ph           piperidine                                       NE
6b    Ph           N-methylpiperazine                       101
6d    Ph              morpholine                                      47
6e    Ph           diethylamine                                    23
Graph 1
Results presented here show that compounds 6 are able to express an evident
structure/activity relationship when evaluated as inhibitors of rat's aortha SMC
proliferation.The p-Bromophenyl substitution at C-5 seems to supply the greatest
contribution to pharmacological activity, and the same does morpholine when
choose as NR2. A further halosubstitution at the ortho position of the phenyl ring
seems to supply a positive contribution as it's shown for compound 6r, but at the
moment this effect has been evaluated only for the dichloro derivative.
Diethylamine seems to increase notably the potency of the derivative as
demonstrated by results on compound 6e.
In the next subchapter will be threated an exhaustive in silico study in order to
describe the potential action mechanism of our 2-pyridinacetamides 6.
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2. Docking of 2-pyridinacetamides to RTK's
In order to confirm our observations upon the mechanism of action of 2-
pyridinacetamides previously sinthetized and to hypotize a potential binding mode
we performed docking experiments on different receptors tyrosine kinase, using the
program AutoDock350, a docking software suitable for deep analysis of single
ligand docking; in fact reported techniques for automated docking fall into two
broad categories: matching methods and docking simulation methods. Matching
methods create a model of the active site, typically including sites of hydrogen
bonding and sites that are sterically accessible, and then attempt to dock a given
inhibitor structure into the model as a rigid body by matching its geometry to that of
the active site. The most successful example of this approach is DOCK51 which is
efficient enough to screen entire chemical databases rapidly for lead compounds.
The second class of docking techniques model the docking of a ligand to a target in
greater detail: the ligand begins randomly outside the protein, and explores
translations, orientations, and conformations until an ideal site is found. These
techniques are typically slower than the matching techniques, but they allow
flexibility within the ligand to be modeled and can utilize more detailed molecular
mechanics to calculate the energy of the ligand in the context of the putative active
site. They allow computational chemists to investigate modifications of lead
molecules suggested by the chemical intuition and expertise of organic synthetic
chemists. AutoDock3 is an example of the latter, more physically detailed, flexible
docking technique. 
Molecular docking is a difficult optimization problem, requiring efficient sampling
across the entire range of positional, orientational, and conformational possibilities.
Genetic algorithms (GA) fulfill the role of global search particularly well and are
increasingly being applied to both drug design and docking. 
Genetic algorithms52 use ideas based on the language of natural genetics and
biological evolution. In the case of molecular docking, the particular arrangement of
a ligand and a protein can be defined by a set of values describing the translation,
50 G.M. Morris et al., J. Comp. Chem., 1998, 19, 1639-1662.
51 a)I. D. Kuntz et al., J. Mol. Biol., 1982, 161, 269.
b)B. K. Shoichet et al., Prot. Eng., 1993 , 6, 723.
52 J. H. Holland, Adaptation in Natural and Artificial Systems, University of Michigan Press, Ann
Arbor, MI, 1975.
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orientation, and conformation of the ligand with respect to the protein: these are the
ligands's state variables and, in the GA, each state variable corresponds to a gene.
The ligand's state corresponds to the genotype, whereas its atomic coordinates
correspond to the phenotype. In molecular docking, the fitness is the total
interaction energy of the ligand with the protein, and is evaluated using the energy
function. Random pairs of individuals are mated using a process of crossover, in
which new individuals inherit genes from either parent. In addition, some offspring
undergo random mutation, in which one gene changes by a random amount.
Selection of the offspring of the current generation occurs based on the individual's
fitness: thus, solutions better suited to their environment reproduce, whereas poorer
suited ones die. A variety of approaches have been adopted to improve the
efficiency of the genetic algorithm. Classical genetic algorithms represent the
genome as a fixed-length bit string, and employ binary crossover and binary
mutation to generate new individuals in the population. Unfortunately, in many
problems, such binary operators can generate values that are often outside the
domain of interest, leading to gross inefficiencies in the search. The use of real
encodings helps to limit the genetic algorithm to reasonable domains. Alternative
genetic algorithms employ more complicated representations and more
sophisticated operators besides crossover and mutation. Some of these retain the
binary representation, but must employ decoders and repair algorithms to avoid
building illegal individuals from the chromosome, and these are frequently
computationally intensive. However, the search performance of the genetic
algorithm can be improved by introducing a local search method.
AutoDock3 can then use a algorithm GA for global searching, a local search LS
method to perform energy minimization, or a combination of both. The local search
method is based on that of Solis and Wets53, which has the advantage that it does
not require gradient information about the local energy landscape, thus facilitating
torsional space search. In addition, the local search method is adaptive, in that it
adjusts the step size depending upon the recent history of energies: a user-defined
number of consecutive failures, or increases in energy, cause the step size to be
doubled; conversely, a user-defined number of consecutive successes, or decreases
in energy, cause the step size to be halved. The hybrid of the GA method with the
53 F. J. Solis and R. J.B. Wets, Math. Oper. Res., 1981, 6, 19.
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adaptive LS method together form the so-called Lamarckian genetic algorithm
LGA, which has enhanced performance relative to simulated annealing and GA
alone. Thus, the addition of these new GA-based docking methods allows problems
with more degrees of freedom to be tackled. Furthermore, it is now possible to use
the same force field as is used in docking to perform energy minimization of
ligands.
Another usefull implementation of AutoDock3 is the empirical free energy function
used for scoring. The study of molecular structure underpins much of computational
molecular biology. There are several established methods for performing molecular
mechanics and molecular dynamics, notably AMBER54, CHARMM55 and
GROMOS56. Many of these traditional force fields model the interaction energy of a
molecular system with terms for dispersion/repulsion, hydrogen bonding,
electrostatics and deviation from ideal bond lengths and bond angles. These
methods are excellent for studying molecular processes over time, for optimizing
bound conformations, and for performing free energy perturbation calculations
between molecules with a single atom change, but they often require considerable
investments of computer time and, unfortunately, these approaches tend to perform
less well in ranking the binding free energies of compounds that differ by more than
a few atoms. What is needed is an empirical relationship between molecular
structure and binding free energy. The first thoroughly established linear free
energy relationship was observed by Hammett in 1933, and reported in 193757. It
was used to relate structure and reactivity of small organic molecules on a
quantitative basis. Hammett was able to derive substituent constants and reaction
constants that could then be used to calculate rate constants and equilibrium
constants for a specific reaction of a specific compound. Hammett's work was the
forerunner of modern- day quantitative structure-activity relationships (QSAR ),
pioneered by Hansch and coworkers in the 1960s. Here it is assumed that the sum of
the steric, electronic, and hydrophobic effects of substituents in a compound
54 W. D. Cornell, P. Cieplak, C. I. Bayly, I. R. Gould, K. M. Merz Jr., D. M. Ferguson, D. C.
Spellmeyer, T. Fox, J. W. Caldwell, and P. A. Kollman, J. Am. Chem. Soc., 1995, 117, 5179.
55 B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus, J.
Comput. Chem., 1983, 4, 187
56 H. J. C. Berendsen, J. P. M. Postma, W. F. van Gunsteren, A.   . diNola, and J. R. Haak, J. Chem.
Phys., 1984, 81, 3684.
57 L. P. Hammett, J. Am. Chem. Soc., 1937, 59, 96.
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determines its biological activity58. Current structure-based scoring functions seek
to remedy some of the deficiencies of traditional force fields by developing
empirical free energy functions that reproduce observed binding constants. Most of
these approaches use an expanded master equation to model the free energy of
binding, adding entropic terms to the molecular mechanics equations:
∆G = ∆Gvdw + ∆Ghbond + ∆G elec + ∆Gconform  + ∆Gtor + ∆Gsol
where the first four terms are the typical molecular mechanics terms for
dispersion/repulsion, hydrogen bonding, electrostatics, and deviations from covalent
geometry, respectively; ∆Gtor models the restriction of internal rotors and global
rotation and translation and ∆Gsol models desolvation upon binding and the
hydrophobic effect solvent. Entropy changes at solute/solvent interfaces . This latter
term is the most challenging. Most softweres use variants of the method of Wesson
and Eisenberg59, calculating a desolvation energy based on the surface area buried
upon complex formation, with the area of each buried atom being weighted by an
atomic solvation parameter. AutoDock3 has implemented a similar approach using
the thermodynamic cycle of Wesson and Eisenberg. The form of this free energy
function is:
where the five ∆G terms on the right-hand side are coefficients empirically
determined using linear regression analysis from a set of protein/ligand complexes
with known binding constants. The summations are performed over all pairs of
58 C. Hansch, A. R. Steward, J. Iwasa, and E. W. Deutsch, Mol. Pharmacol., 1965, 1, 205.
59 L. Wesson and D. Eisenberg, Prot. Sci., 1992, 1, 227.
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ligand atoms, i, and protein atoms, j, in addition to all pairs of atoms in the ligand
that are separated by three or more bonds. The in vacuo contributions include three
interaction energy terms: a Lennard-Jones 12-6 dispersion/repulsion term; a
directional 12-10 hydrogen bonding term, where E (t) is a directional weight based
on the angle, t, between the probe and the target atom; and a screened Coulombic
electrostatic potential. A measure of the unfavorable entropy of ligand binding due
to the restriction of conformational degrees of freedom is added to the in vacuo
function. This term is proportional to the number of sp3 bonds in the ligand, Ntor .
Ehbond is the estimated average energy of hydrogen bonding of water with a polar
atom, and the summation in the solvation term is performed over all pairs consisting
of only carbon atoms in the ligand, i, and atoms of all types, j, in the protein. Note
that the internal or intramolecular interaction energy of the ligand is not included in
the calculation of binding free energy; during docking, however, internal energy is
included in the total docked energy, because changes in ligand conformation can
affect the outcome of the docking, so this must be taken into consideration. The
assumption made is that the internal energy of the ligand in solution and in the
complex are the same. The energies used and reported by AutoDock3 should be
distinguished: there are docked energies, which include the intermolecular and
intramolecular interaction energies, and which are used during dockings; and
predicted free energies, which include the intermolecular energy and the torsional
free energy. Such scoring function is then claimed to be able to correctly predict
inhibitors ki with enough accuracy to discriminate between millimolar, micromolar
and nanomolar inhibitors.
Target structures, when available, were downloaded from the Protein Data Bank
(PDB)60. PDGFRK crystallographic structure as not been resolved yet, then it has
been constructed by homology modelling using PDB files 1AGW (FGFRK) and
1VR2 (VEGFR2K) as templates for the catalytic domain. The program
Modeller6v261 was used for homology modelling with alignments generated with
T-COFFEE62 as it's throughly described in the experimental section. 
Human EGFRK, PDGFRK, VEGFR2K and FGFR1K, have been considered in this
60 H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, P.E.
Bourne:The Protein Data Bank, Nucleic Acids Research, 2000, 235-242.
61 A. Šali and T.L. Blundell, J. Mol. Biol., 1993, 234, 779-815.
62 C. Notredame, D. Higgins, J. Heringa, Journal of Molecular Biology, 2000, 302, 205-217.
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docking study. The protocol used has been validated by reproducing the binding
mode of the cocrystallized inhibitor if present in the PDB file, or otherwise by
reproducing dockings present in litterature63. Ligands has been constructed using the
commercial program LINMOPAC from Fujitsu. Geometries has been optimized
using the semiempirical theory with the Austin Model 164 (AM1) to a gradient of
0.01 with the commercial program MOPAC2002. Partial charges has been derived
from electrostatic potential calculated ab-initio at the HF/6-31G* level of theory23
using the program GAMESS21, according to the Merz-Kollman procedure65, this
because one key criterion for molecular simulations is the accurate description of
the electrostatic potential around the solute, achieved by the so-called potential
derived atomic charges obtained from a least-squares fit to the quantum
mechanically determined molecular electrostatic potential, discretized on a grid of
points, and targeted at the faithful reproduction of the latter quantity. Such is
generally the case for polar systems, in which the local multipoles borne by each
atomic site can be represented satisfactorily by a simple set of atom-centered point
charges. The approximation that the electrostatics of the system formed by the
solute and the solvent could be reduced to a sum of pairwise Coulomb interactions
neglects, however, the polarization of the neighboring solvent molecules by the
solute, and, in turn, the polarization of the solute by its surroundings. Employing the
most accurate geometry and ab initio wave function, the one guaranteeing a correct
reproduction of the molecular multipole moments of the solute in the gas phase, one
clearly cannot hope to describe satisfactorily such intermolecular induction effects.
To circumvent this difficulty, Kollman et al. suggest that electrostatic potential
derived charges computed at the restricted Hartree Fock (RHF) level of
approximation, using the split-valence 6-31G* basis set, could allow polarization
effects to be included in molecular mechanical simulations in an average manner.
This heuristic method is based on the observation that dipole moments evaluated at
this level of theory generally overestimate the corresponding experimental
quantities by 10-15%, thereby increasing artificially the polarity of the solute and
compensating for the missing induction term in the force field.
63 Brian D. Palmer et al., J. Med. Chem., 1999, 42, 2373-2382
64M.J.S. Dewar, E.G. Zoebisch, E.F. Healy and J.J.P. Stewart,  J. Am. Chem. Soc., 1985,  107, 3902
65 a)Besler, B. H.; Merz Jr., K. M.; Kollman, P. A. J Comput Chem, 1990, 11, 431. 
      b)Merz, K. M. J Comput Chem , 1992, 13, 749.
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2-Pyridinacetamides included in this docking study are represented in Figure 1
below.
Figure 1: 2-Pyridinacetamides considered for docking to receptors tyrosine kinase 
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Docking of 2-Pyridineacetamides to EGFRK
Cristal structures of EGFRK alone or complexed with it's inhibitor Tarceva®
(Erlotinib)66 have been recently resolved and made available on the Protein Data
Bank, respectively as 1M14 and 1M17. The EGFRK kinase domain adopts the
bilobate-fold characteristic of all previously reported protein kinase domains. The
NH2-terminal lobe (N-lobe) is formed from mostly β-strands and one α-helix (αC),
whereas the larger COOH terminal lobe (C-lobe) is mostly α-helical. The two lobes
are separated by a cleft similar to those in which ATP, ATP analogues, and ATP-
competitive inhibitors have been found to bind. Important elements of the catalytic
machinery bordering the cleft on the N-lobe include the glycine-rich nucleotide
phosphate- binding loop (Gly695-Gly700), whereas the C-lobe contributes the DFG
motif (Asp831-Gly833), the presumptive catalytic (general base) Asp813, the
catalytic loop (Arg812-Asn818), and the A-loop (Asp831-Val852). The NH2-
terminal lobe of EGFRK adopts a tertiary structure similar to previously observed
structures of RTKs (r.m.s. deviations for superpositioning C-α atoms with the
kinase domain from the fibroblast growth factor receptor is about 1.2 Å), although a
few features distinguish the N-lobe of EGFRK from other kinase domains. The
NH2-terminal nine amino acids are influenced by several intermolecular contacts
including H-bonds involving main chain atoms of residues Asn676 and Leu680,
although intramolecular H-bonds between Asn676 and both Tyr740 and Ser744 also
contribute. At Glu685, the polypeptide chain assumes a trace more similar to those
of the lymphocyte tyrosine kinase (LCK, PDB code 3lck), the insulin receptor
kinase-phosphorylated form (p-IRK, PDB code 1ir3), and the unphosphorylated
form of the FGF receptor kinase (FGFRK, PDB code 1fgk). However, EGFRK
lacks the tryptophan- glutamate ( WE ) motif found in these related kinases, and has
Arg681-Ile682 instead. In the WE-containing kinases, hydrophobic interactions of
the tryptophan and an H-bond between the glutamate and a threonine or serine and
the neighboring β-strand tie the NH2-terminal region to the N-lobe. In EGFRK
Arg681 projects into solvent, but Ile682 contacts Leu782 and Ile756 on the
neighboring β-strand and thereby affords a similar effect. Among the canonical
features characterizing the N-lobes of active forms of kinases is a salt bridge
between two highly conserved side chains that interact with the α- and β-phosphates
66 J. Stamos, M. X. Sliwkowski, and C. Eigenbrot, JBC, 2002, 277, 46265-46272.
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when ATP or a close homologue is present. Such salt bridge inhibitor-bound forms
of EGFRK, between Lys721 and Glu738 is present in both ligated and unligated
structure, suggesting that EGFRK does not require large rearrangements within the
N-lobe for catalytic competence. The COOH-terminal domain of EGFRK contains
the usual organization of α-helices present in other kinase domain structures.
Superpositioning of the C-lobes of kinase domains from both LCK and p-IRK yield
a r.m.s. deviation of 1.1 Å. However, as with the N-lobe, a few key features differ
from previously elucidated RTK structures. In most protein kinases, the activation
loop assumes its catalytically competent conformation only if it first becomes
phosphorylated on a Tyr or Thr. For these kinases, the unphosphorylated activation
loop is positioned many Angstroms from the active conformation and may include a
direct inhibitory element. For instance, the unphosphorylated A-loop in FGFRK is
incompatible with substrate binding, and the unphosphorylated insulin receptor
kinase A-loop blocks ATP binding as well as the substrate tyrosine site. The A-loop
in ligated and unligated EGFRK differs significantly from other unphosphorylated
A-loop structures and adopts an active conformation similar to the phosphorylated
A-loop of p-IRK. The well conserved sequence of the EGFRK catalytic-loop
(HRDLAARN), also present in p-IRK and FGFRK, shares structural conservation
with these RTKs as well with a r.m.s. deviation of most atoms of only 0.1 Å. The
nearby conserved DFG sequence, important for ATP coordination, adopts the p-
IRK-like arrangement. well with a r.m.s. deviation of most atoms of only 0.1 Å. The
principle difference between the p-IRK and EGFRK structures in this region is in
the nucleotide phosphate-binding loop. 
Figure 2 shows interactions between Tarceva and EGFRK. 4-anilinoquinazolines
such as Tarceva cause inhibition through binding to the site occupied by ATP
during phosphotransfer. Tarceva lies with the N-1- and C-8-containing edge of the
quinazoline directed toward the peptide segment connecting N- and C-lobes, with
the ether linkages projecting past the connecting segment into solvent and the
anilino substituent on the opposite end sequestered in a hydrophobic pocket. The N-
1 of the quinazoline accepts an H-bond from the Met769 amide nitrogen. The other
quinazoline nitrogen atom (N-3) is not within H-bonding distance of the Thr766
side chain (4.1 Å), but a water molecule bridges this gap. Such a water molecule
contacts the side chain of Cys751. The less robust nature of this water-mediated H-
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bond between Tarceva and EGFRK parallels the relatively small effect on inhibitor
affinity seen for substitution with carbon for N-3 among compounds characterized
by Rewcastle et al67.
Figure 2:  interactions between Tarceva and EGFRK active site
The interplanar angle of aromatic ring systems in Tarceva is 42°. This directs the
acetylene moiety into a pocket that many kinase domains share when the amino acid
side chain at position 766 is small (threonine in EGFRK). Thr766, Lys721, and
Leu764 are 4 Å from the acetylene moiety on the anilino ring (Thr766 and Leu764
are 3.4 Å). 
Our first task was then to validate our docking protocol by reproducing accurately
the binding mode of the inhibitor cocrystallized with EGFRK as reported above. 
Current docking procedure is to remoove all non-protein atoms from the PDB file,
thus including water molecules, but a recent study68 conducted at the ETH by Prof.
67 G. W. Rewcastle et al.,J. Med. Chem., 1995, 38, 3482 3487.
68 P. Pospisil, T. Kuoni, L. Scapozza and G. Folkers.,J. Receptor & Signal Transduction Res.,
68
Folkers and Scapozza revealed the importance that water molecules could play in
molecular docking. Has been reported above that a water molecule bridges the gap
between Tarceva's N-3 and the Thr766 side chain. Furthermore such water is
present either in the ligated and unligated structure of EGFRK with superposable
coordinates, suggesting that this water molecule could be a structural and not only
crystallization water. For those reasons we set up two docking experiments, one
following the standard procedure (removal of all water from the PDB file) and one
keeping the water molecule H-linked to Thr766 (water number 10 in the PDB file).
Figures 3 and 4 show resulted “top 5” docked structure s of Tarceva in the EGFRK
active site. It's evident from Figure 3 that the ligand docks in a really disordered
way, each structure assuming different orientations and not allowing the obtainment
of a significative cluster of conformations to describe the binding mode. Moreover
only one structure assume an orientation close to that described by crystallography.
2002, 22, 141-154.
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Figure 3: Docking of Tarceva to the EGFRK active site without considering water 
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Figure 4 shows “top 5” results obtained by a docking run considering water 10 as a
part of the active site during calculations of grids of potential necessary for
AutoDock3 calculation and water parameters are taken from the well tested Amber
force field. Results from this run are enthusiasting, as all of the 50 conformations
obtained from the calculation are within a rmsd of 0.5 with the reference
crystallographic compound. The major differences occur at the sidechains,
extremely flexible and probably allowed to move; this observation could be
confirmed by the absence of description of any role of those in the receptor binding,
and they probably constitute the aptophore moiety of the drug.
Figure 4: Docking of Tarceva to the EGFRK active site considering water 10
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Those results confirm the validity of the docking protocol used, as it has been
possible to highly reproduce the binding mode of Tarceva as described by
crystallographic resolution.
In order to assess if the presence or absence of water 10 could affect also docking of
2-pyridinacetamides we performed a docking run on the compound CA1Gd
considering or not water 10 as a part of the active sites. “Top 5” structures resulted
from both calculations are represented in Figures 5 and 6, and the importance of the
presence of water bridge between Thr766 and inhibitor results even more evident.
The distance observed between pyridin's N and water's H is of about 3 Å, probably
a distance to high to hypotize a real H-bond, but enough to stabilize the orientation
of compound CA1Gd inside the binding pocket. Susseguent calculations has then
been made considering water 10 as constitutive of the active site.
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Figure 5: Docking of CA1Gd to the EGFRK active site without considering water
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Figure 6: Docking of CA1Gd to the EGFRK active site considering water 10
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All 2-pyridineacetamides reported in figure 1 has been docked to EGFRK and
results are summarized in Table 1 and represented graphically in Graph1
Table 1: Docking of 2-Pyridinacetamides to the EGFRK active site:
               energy results and scoring
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Ki x10e6 Dock. Eg Mol/cluster Cluster Rank
CA62 NH 0.1 -11.09 33 1
CA1G NO 0.11 -11.82 26 1
CA16 0.45 -12.12 12 2
Tarceva 0.61 -10.77 8 1
CA37 c 0.66 -12.06 18 2
CA60 0.96 -0.97 7 2
CA55 1.04 -10.46 16 1
CA17 1.34 -11.7 29 1
CA23 f 1.64 -11.53 20 2
CA1G d 1.79 -11.33 18 1
DC48II 1.84 -11.53 38 1
DC65II 1.89 -11.48 20 1
KL15 2.02 -11.48 25 1
KL19 2.03 -11.48 22 1
CA2G 2.08 -11.5 31 1
CA57 2.15 -10.99 18 2
CA32 FII 2.58 -11.42 21 1
CA50 c T 3.08 -11.19 7 1
CA32 FII 3.32 -11.5 7 9
CA54 4.42 -11.01 29 1
CA1G MP 4.49 -10.86 14 1
CA58 5.73 -10.44 8 1
CA5 c 7.82 -10.41 41 1
CA53 T 8.13 -10.44 32 1
Graph1: Docking of 2-Pyridinacetamides to the EGFRK active site:
               energy results and scoring
Graph1 represents predicted Ki (blue) compared with resulted docked energy (red).
In order to assign correct scoring to docked compounds it's necessary to consider
always more than one scoring function; for example in graph 1 compound CA60
shows a really low Ki, but high docked energy suggest really unfavorable steric
clashes for the resulted complex. For greater accuracy it's also important to consider
the maximum number of conformations per cluster (wich shows how well is
reproduced a paticular conformation inside the docking run) and the energy ranking
of the most representative cluster. Anyway a visual inspection of results is a must fo
a correct interpretation; in fact, docking of Tarceva seems to result a poor cluster of
conformations, but this is due to the high flexibility of side chains and considering
the quinazoline pharmacophoric nucleus it's correctly docked for more than 40
conformations, compared with cristallographic results. 
It's interesting to notice how well tested 2-pyridineacetamides fit in the EGFRK
active site: most of them show clusters of more than 20 orientations, ranked as first
or second in energy. Scoring is also interesting: in the top 10 results are reported the
reference compound Tarceva (ERL), CA16, CA37c, CA55, CA23 F, CA1G D, all
resulted active at the pharmacological tests on SMC proliferation; CA62 NH, CA1G
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NO and CA60 has never been tested and CA17 resulted completely inactive.
Unfortunatly the compound resulted more potent in cellular assays it's ranked only
16th, however we have to consider that docking assays are a model for reproducing
binding assays on purified enzyme, being the cellular model more complicated,
since must be considered also the ability of tested compounds to reach the target
enzyme (membrane permeation, interaction with other binding sites, enzymatic
degradation etc.). However, generally predicted results are in good agreement with
pharmacological results.
It should be noticed that conformations resulted from docking of 2-
pyridineacetamides and ranked as reported in Table 1, present all the same
orientation inside the active site of EGFRK, and this could be considered as another
proof of the accuracy of those successfull run. In fact it has been possible to
describe a common binding mode for all compounds.
Figures 7 depicts compound CA1G d docked in EGFRK's active site cavity, while
Figure 8 describe the proposed binding mode for CA1Gd, but we generally
observed the same interactions for all 2-pyridineacetamides included in this
docking. 
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Figure 7: Compound CA1Gd docked inside EGFRK's active site cavity
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Figure 8: Proposed binding mode for 2-Pyridinacetamides to EGFRK. Compound
                CA1Gd is shown as example
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As shown in figure 8, main interaction observed are:
• H-bond between Met769 and morpholine-6 oxigen
• H-bond between Lys721 and amidic C=O
• H-bond brdged by water between Thr766 and pyridine's N
• Hydrophobic interactions between Leu820 and Val702 with pyridine nucleus
• Hydrophobic interactions between Leu694 and the aromatic substituent at C-5.
The proposed binding mode is in agreement with the reported binding mode for
literature compounds described in Chapter 2 and 3, as it involves or the same
aminoacids or aminoacids close to them, well inside the active site. This hypotized
binding mode is also reasonable considering the absence of pharmacological
activity on SMC proliferation assays for all 2-pyridineacetamides lacking of the
aromatic substituent at C-5 position.
A potential improvement to the docking of 2-pyridineacetamides in the active site
of EGFRK could be done by an opportune substitution at the pyridine nitrogen with
a polar chain, in order to displace water and bind threonine OH. This could yield a
great gain in docking energy due to a further H-bond and to the entropic
contribution caused by the expulsion of water from the active site. However such
substitution could be done only by generating a salt (i. e. by a nucleophilic addition
to an epoxyde of the pyridin nitrogen) that would encounter much more difficulties
in permeating cellular membranes and thus in reaching tyrosin kinase receptors. 
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Docking of 2-Pyridineacetamides to PDGFRK
Docking of compounds reported in Figure 1 to PDGF receptor kinase required
particular attention, as a model of the structure has to be constructed due to the lack
of crystal structures. Homology modelling is the most reliable technique for
generating protein models for docking purposes, allowing the prediction of the 3D
structure of a given protein sequence (target) based primarily on its alignment to
one or more proteins of known structure (templates). The prediction process
consists of fold assignment, target-template alignment, model building, and model
evaluation. The number of protein sequences that can be modeled and the accuracy
of the predictions are increasing steadily because of the growth in the number of
known protein structures and because of the improvements in the modeling
software. It is currently possible to model with useful accuracy significant parts of
approximately one half of all known protein sequences69. 
Despite progress in ab initio protein structure prediction70, comparative modeling
remains the only method that can reliably predict the 3D structure of a protein with
an accuracy comparable to a low-resolution experimentally determined structure71.
The starting point in comparative modeling is to identify all protein structures
related to the target sequence, and then select those structures that will be used as
templates. 
There are three main classes of protein comparison methods that are useful in fold
identification: 
1. The first class includes the methods that compare the target sequence with each
of the database sequences independently, using pairwise sequence-sequence
comparison72. Frequently used programs in this class include FASTA 73 and
BLAST 74.
2. The second set of methods relies on multiple sequence comparisons to improve
the sensitivity of the search75. A widely used program in this class is PSI-
69 U. Pieper et al., Nucleic Acids Res., 2002, 30, 255-259
70 a) D. Baker, Nature, 2000, 405, 39-42 
b) R. Bonneau and D. Baker,Annu. Rev. Biophys. Biomol. Struct., 2001, 30, 173-189
71 M. A. Marti-Renom et al., Annu. Rev. Biophys. Biomol. Struct., 2000, 29, 291-325
72 A. Apostolico and R. Giancarlo, J. Comput. Biol., 1998, 5, 173-196
73 a) W. R. Pearson and D. J. Lipman, Proc Natl Acad Sci USA, 1988, 85, 2444-2448
b) W. R. Pearson, Protein Sci., 1995, 4, 1145-1160
74 S. F. Altschul et al., J. Mol. Biol., 1990, 215, 403-410
75 L. Rychlewski et al., Fold Des., 1998, 3, 229-238 and ref. cited therein
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BLAST, which iteratively expands the set of homologs of the target sequence.
For a given sequence, an initial set of homologs from a sequence database is
collected, a weighted multiple alignment is made from the query sequence and its
homologs, a position specific scoring matrix is constructed from the alignment,
and the matrix is used to search the database for additional homologs. These
steps are repeated until no additional homologs are found. In comparison to
BLAST, PSI-BLAST finds homologs of known structure for approximately
twice as many sequences 76.
3. The third class of methods is the so-called threading or 3D template matching
methods77. These methods rely on pairwise comparison of a protein sequence and
a protein of known structure. Whether or not a given target sequence adopts any
one of the many known 3D folds is predicted by an optimization of the alignment
with respect to a structure dependent scoring function, independently for each
sequence-structure pair. That is, the target sequence is threaded through a library
of 3D folds.
This latter method is included in the program Modeller6V2 inside the
SEQ_SEARCH routine. These methods are especially useful when there are no
sequences clearly related to the modeling target, and thus the search cannot benefit
from the increased sensitivity of the sequence profile methods. A useful fold
assignment approach is to accept an uncertain assignment provided by any of the
methods, build an all-atom comparative model of the target sequence based on this
match, and make the final decision about whether or not the match is real by
evaluating the resulting comparative model78. 
Once a list of all related protein structures was obtained, it is necessary to select
those templates that are appropriate for the given modeling problem. Usually, a
higher overall sequence similarity between the target and the template sequence
yields a better model. The quality of the experimental template structure is another
important factor in template selection. The resolution and the R-factor of a
76 a) J. Park et al., J. Mol. Biol., 1998, 284, 1201-1210
b) M. J. Sternberg et al., Curr. Opin. Struct. Biol., 1999, 9, 368-373
77 a) J. U. Bowie et al., Science, 1991, 253, 164-170
b) D. T. Jones et al., Nature, 1992, 358, 86-89
c) A. Godzik et al., J. Mol. Biol., 1992, 227, 227-238
78 a) R. Sanchez and A. Sali, Curr. Opin. Struct. Biol., 1997, 7, 206-214
b) B. Guenther et al., Cell, 1997, 91, 335-345
c) J. M. Miwa et al., Neuron, 1999, 23, 105-114
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crystallographic structure and the number of restraints per residue for an NMR
structure are indicative of its accuracy. If the model is to be used to analyze the
geometry of the active site of an enzyme, it is preferable to use a high-resolution
template. Furthermore the use of several templates approximately equidistant from
the target sequence generally increases the model accuracy 79.
The second step in model building is generating a correct target-template alignment.
Most fold assignment methods produce an alignment between the target sequence
and template structures. However, this alignment is often not the optimal target-
template alignment for comparative modeling. Searching methods are usually tuned
for detection of remote relationships, not for optimal alignments. Therefore, once
templates have been selected, a specialized method should be used to align the
target sequence with the template structures80. For closely related protein sequences
with identity higher than 40%, the alignment is almost always correct. Regions of
low local sequence similarity become common when the overall sequence identity
is below 40%81. The alignment becomes difficult in the twilight zone of less than
30% sequence identity82. As the sequence similarity decreases, alignments contain
an increasingly large number of gaps and alignment errors, regardless of whether
they are prepared automatically or manually. For example, only 80% of the residues
are likely to be correctly aligned when two proteins share 30% sequence identity83.
Maximal effort to obtain the most accurate alignment possible is needed because no
current comparative modeling method can recover from an incorrect alignment. In
the more difficult alignment cases, it is frequently beneficial to rely on multiple
structure and sequence information84. 
First, the alignment of the potential templates is prepared by superposing their
structures. Next, the sequences that are clearly related to the templates and are
easily aligned with them are added to the alignment. The same is done for the target
sequence. Finally, the two profiles are aligned with each other, taking structural
information into account as much as possible85. 
79 N. Srinivasan and T. L. Blundell, Protein Eng., 1993, 6, 501-512
80 T. F. Smith, Structure Fold Des., 1999, 7, R7-R12 and ref cited therein
81 M. A. Saqi et al., Protein Eng., 1998, 11, 627-630
82 B. Rost, Protein Eng., 1999, 12, 85-94
83 M. S. Johnson and J. P. Overington, J. Mol. Biol., 1993, 233,716-738
84 W. R. Taylor et al., Protein Sci., 1994, 3, 1858-1870 and ref cited therein
85 Sali, A., Fiser, A., Sanchez, R., Marti-Renom, M. A., Jerkovic, B., Badretdinov, A., Melo, F.,
Overington, J., and Feyfant, E. MODELLER, A Protein Structure Modeling Program, Release
6v2. 2002. http://guitar.rockefeller.edu/modeller/.
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Third step is generating models for target structure, and a variety of methods can be
used to construct a 3D model for the target protein. The original and still widely
used method is modeling by rigidbody assembly86. Another family of methods,
modeling by segment matching, relies on the approximate positions of conserved
atoms in the templates87. The third group of methods, modeling by satisfaction of
spatial restraints, uses either distance geometry or optimization techniques to satisfy
spatial restraints obtained from the alignment88, and this latter is the one used by
Modeller6V2, however accuracies of the various model building methods are
relatively similar when used optimally89. Other factors, such as template selection
and alignment accuracy, usually have a larger impact on the model accuracy,
especially for models based on less than 40% sequence identity to the templates. 
Last but not least in homology modelling is the model evaluation. The first step in
model evaluation is to determine if the model has the correct fold90. A model will
have the correct fold if the correct template is picked and if that template is aligned
at least approximately correctly with the target sequence. The confidence in the
model fold is generally increased by a high sequence similarity to the closest
template, a pseudo-energy Z-score91, and conservation of the key functional or
structural residues in the target sequence. Once the fold of a model is accepted, a
more detailed evaluation of the overall model accuracy can be obtained based on the
similarity between the target and template sequences90. Sequence identity above
30% is a relatively good predictor of the expected accuracy. The reasons are the
well known relationship between structural and sequence similarities of two
proteins92, the geometrical nature of modeling that forces the model to be as close to
the template as possible93, and the inability of any current modeling procedure to
recover from an incorrect alignment78. The dispersion of the model-target structural
overlap increases with the decrease in sequence identity. If the target-template
sequence identity falls below 30%, the sequence identity becomes unreliable as a
measure of expected accuracy of a single model. Models that deviate significantly
86 J. Greer, Proteins, 1990, 7, 317-334 and ref cited therein
87 M. Levitt, J. Mol. Biol., 1992, 226, 507-533 and ref cited therein
88 A. Kolinski et al., Proteins, 2001, 44, 133-149 and ref cited therein
89 Marti-Renom et al., Structure, 2002, 10, 435-440
90 R. Sanchez and A. Sali, Proc Natl Acad Sci U S A , 1998, 95, 13597-13602
91 M. J. Sippl, Proteins, 1993, 17, 355-362
92 C. Chothia and A. M. Lesk, EMBO J., 1986, 5, 823-826
93 A. Sali and T.L. Blundell, J. Mol. Biol., 1993, 234, 779-815
84
from the average accuracy are frequent. It is in such cases that model evaluation
methods are particularly useful. A basic requirement for a model is to have good
stereochemistry. Some useful programs for evaluating stereochemistry are
PROCHECK94, PROCHECK-NMR and AQUA , SQUID95, and WHATCHECK96.
The features of a model that are checked by these programs include bond lengths,
bond angles, peptide bond and sidechain ring planarities, chirality, mainchain and
sidechain torsion angles, and clashes between non-bonded pairs of atoms. There are
also methods for testing 3D models that implicitly take into account many spatial
features compiled from high resolution protein structures. These methods are based
on 3D profiles and statistical potentials of mean force97. Programs implementing
this approach include VERIFY3D98 and PROSAII91. The programs evaluate the
environment of each residue in a model with respect to the expected environment as
found in the high-resolution X-ray structures.
In the present work the catalitic domain was then modelled from high homologue
PDB files 1AGW chain A (FGFR K) and 1VR2(VEGFRK) as templates, using the
program Modeller6V2. A strenght of this program is the ability to consider multiple
templates alignments as input, and thus generating more significative models
compared with those generated using single templates. Templates were identified
using the SEQ_SEARCH routine as implemented in modeller. Several models were
generated and checked with the program PROCHECK94. The best model was then
validated trying to reproduce the theoretical binding mode proposed by Palmer at al
for compound 2299 depicted in Figure 9.
94  Laskowski et al., Curr. Opin: Struct. Biol., 1998, 8, 631-639
95 T. J. Oldfield, J. Mol. Graph., 1992, 10, 247-252
96 R. W. Hooft et al., Proteins, 1996, 26, 363-376
97 M. J. Sippl, J. Mol. Biol., 1990, 213, 859-883
98 R. Luthy et al., Nature, 1992, 356, 83-85
99 Brian D. Palmer et al., J. Med. Chem., 1999, 42, 2373-2382
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The docking run provided doubtful results, because
more than 2 possible orientations were predicted and
two of them gave paragonable results. In order to
discriminate the most favored orientation both
complexes (called hear for semplicity dock1 and
dock2) were minimized using Parm99111 and
GAFF105 forcefields with the program Sander
included in the Amber7 package and a short
molecular dynamic simulation was performed using
the Generalized Born Solvation Model112 in order to include solvent effects.
Resulting structures were minimized again to a gradient of 0.1. Energy of both
conformations was then evaluated semiempirically at PM5100 theory level using the
program MOPAC2002. The algorithm MOZYME implemented in MOPAC2002 is
able to solve SCF large systems in a reasonable time, by the way of a linear scaling
method. In this method, the time required for calculating the SCF increases linearly
with the size of the system. The memory demand is also considerably reduced (for
the larger systems run, by 97 to 98 percent of what would be needed
conventionally). This allows systems of many thousands of atoms to be calculated
rapidly101.
PM5 calculations predicted an energy difference Egdock1-Egdock2 of 12.348 Kcal/mol
in favor of the dock2 complex, that was choosen as docking model. Compound 22
was then docked to this structure and a single conformation was predicted, with a
binding mode in agreement with litterature results. All 2-pyridineacetamides
reported in figure 1 has then been docked to PDGFRK model and results are
summarized in Table 2 and represented graphically in Graph2.
100J. J. P. Stewart, Meth. J. Comput. Chem., 1989, 10, 209
101J. J. P. Stewart, Mopac2002 program manual.
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Table 2: Docking of 2-Pyridinacetamides to PDGFRK; energy results and scoring
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Ki x10e6 Dock. Eg Mol/clust clust/rank
CA60 0.2 -1.6 21 1
CA37c 0.25 -11.42 27 3
CA32 f 0.3 -11.08 46 1
CA16 0.38 -11.01 43 1
CA62 0.4 19.61 6 24
CA62_NH 0.41 -10.6 10 2
DC48II 0.43 -10.54 10 1
KL15 0.45 -10.64 42 2
CA32fII 0.47 -11.57 3 8
CA2 g 0.52 -10.47 26 2
CA17 0.6 -10.38 23 6
CA23 f 0.68 -10.55 23 5
CA1g d 0.86 -10.34 29 2
CA1g NO 1.06 -10.4 35 5
CA57 1.06 -10.16 17 4
CA53 T 1.12 -9.58 18 2
DC65II 1.18 -10.23 10 11
CA50c t 1.41 -10.32 11 1
Kl19 1.79 -9.99 11 14
CA1g MP 1.83 -9.97 19 4
CA5 c 2.32 -9.23 23 2
CA54 2.76 -9.94 14 8
CA58 4.07 -9.84 25 4
CA55 10.5 -9.02 9 17
22 10.9 -7.3 34 1
Graph 2: Docking of 2-Pyridinacetamides to PDGFRK; energy results and scoring
Results in this case are less clean, compared to those obtained from EGFRK. It can
be noted from Table 2 that number of conformations per cluster are lower and
cluster ranking is higher, however few compounds provided even better results:
docking of CA32 f, CA16 and KL15 resulted in more than 40 conformations per
cluster with an optimal ranking, while the same provided respectively 21, 12 and 25
conformations per cluster when docked to EGFRK . Furthermore all compounds
having a significative clustering (e. g. more than 25 conformations/cluster) show the
same binding mode, as represented in Figure 10 for compound CA32 f.
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Figure 10: Proposed binding mode for 2-Pyridinacetamides to PDGFRK.
                  Compound CA32 f is shown as example
Observed interactions are:
• H-bond between C-6 linked morpholine oxygen and Asp844
• Electrostatic interaction between C-6 linked morpholine nytrogen and Cys843
• Hydrophobic interactions between aromatic C-5 substituent and aminoacids
Leu606, Leu833 and Val665 forming an hydrophobic pocket.
• Hydrophobic interactions between Val614 and pyridine nucleus
• Hydrophobic interactions between the amidic substituent and a lipophilic pocket
formed by Phe611, Leu648 and Ile679
Electrostatic interactions appear to be pretty weak, considering the relative long
distance between morpholine oxygen and amidic N-H of Asp844 (2.07 Å) and the
greater distance between morpholine nitrogen and the S-H moiety of Cys843 (3.85
Å). However hydrophobic interactions seems to be more important, as it can be
better appreciated by the molecular surface representations reported in Figures 11
and 12, respectively inherent to docked litterature compound 22 and compound
CA32 f. Hydrophobic pocket formed by aminoacids Leu606, Leu833 and Val665
it's well evident on the left side of the pictures below, while Phe611, Leu648 and
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Ile679 form the cavity hosting the amidic substituent of compound CA32 f and
visible on the right.
Figure 11: Literature compound 22 docked into the PDGFRK cavity.
                  A molecular surface representation
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Figure 12: Compound CA32 f docked into the PDGFRK cavity.
                  A molecular surface representation
It could be noticed from Figures 11 and 12 that compound CA32 f fits much better
inside the binding site, assuming a conformation similar to an “embrace” that fill
properly both right and left hydrophobic pockets respectively with the
halosubstituted phenyl ring and the amidic N-methyl piperazine. This could
explainthe much lower Ki and docking energy values predicted by AutoDock if
compared with the benzoimidazol derivative 22 represented in Figure 9.
However it could also be noticed that the C-4 methyl substituent and the C-4 itself
seem to cause a steric clash with the upper part of the cavity. It could be interesting,
in this case, to explore the docking behavior of a five membered ring pyridine
bioisoster, such as a pyrrole, applying a classical QSAR technique for lead
optimization.
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Docking of 2-Pyridineacetamides to VEGFRK
On the basis of sequence homology and overall domain structure, VEGFR belong to
the platelet derived growth factor receptor family (PDGFR). CrYstal structure of
VEGFR 2 has been resolved41 with a resolution of 2.4 Å and deposed as PDB file
1VR2. The crystal structure has been determined in an unligated but phosphorylated
state. Analogous to other protein kinases VEGFR2 is folded into two lobes, with the
active site placed in a cleft between the two lobes. Like other kinases, VEGFR2
contains other functionally important loop regions: the nucleotide binding loop
(residues 841-846), the catalytic loop (residues 1026-1033) and the activation loop
(residues 1046-1075). However authors state that the kinase activation loop
phorylated on tyrosine 1059 was disordered and thus not properly resolved.
Furthermore it can be noticed that a portion of it occupies a position inhibitory to
substrate binding. Litterature does not report detailed binding mode for any known
inhibitor, however authors report that crystal structure of VEGFR2 resembles most
closely that of the catalitic domain of FGFR1 resolved by Hubbard et al. in complex
with adenylyl methylenediphosphate (AMP-PCP)102 and in another work complexed
to known inhibitors SU4984 and SU5402103. VEGFR2 and FGFR1 share
approximately 55% sequence identity, and a least square superposition of 82 Cα
positions of strands (β1-β5) of the N-terminal lobe or 152 Cα positions of helices
(αD, αE, αF, αG, αH, αI ) of the C-terminal lobe between FGFR1 and crystal
structure of VEGFR2 result in respective root mean square deviation (r.m.s.d.)
values of 0.40 Å and 0.52 Å. 
102M. Mohammadi, J. Schlessinger, S.R. Hubbard, Cell., 1996, 86, 577.
103S.R. Hubbard, J. Schlessinger et al., Science, 1997, 276, 955-960
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Figure 13
Hubbard reports that SU5402 is a selective
inhibitor of FGFR1, because the hydrogen bond
between the side chain amide of asparagine 568
in the hinge region of FGFR1 and the
carboxyethyl group of SU5402, represented in
Figure 13, confer this specificity. In PDGFRK
the residue at the position corresponding to
Asn568 is an aspartic acid, witch at neutral pH
will not form hydrogen bonds with the
carboxyethyl group. However Hubbard reports
also that VEGFR has an asparagine in this
position and that SU5402 is a potent VEGFR
inhibitor in living cells.
For the reasons stated above we used molecular modelling and molecular dynamics
tools to describe the binding mode of SU5402 to the active site of VEGFR2. This
must be done in order to obtain informations useful to validate any result produced
by docking of our 2-pyridineacetamides to VEGFR 2 kinase.
As the VEGFR2K cristal structure resolved by McTigue presented many disordered
residues we constructed a complete homology model based on templates 1VR2
(VEGFR 2K) and 1AGW (FGFR1K) with the program Modeller6V2 using
alignments generated with the program T-COFFEE as previously described for
PDGFR model. A least square superposition of Cα atoms of both reported cristal
structures 1VR2 and 1AGW with our model resulted in respective root mean square
deciation values of 0.54 Å and 1.15 Å, while a superposition of Cα atoms of 1VR2
and 1AGW resulted in rmsd value of 0.99 Å , confirming that the generated model
conserved properly the conformation of templates. 
Ligand SU5402 was extracted from the PDB file (1FGI), hydrogens were added
using Autodock Tools and molecular mechanics parameters were derived using
with the program Antechamber104 included in the Amber7 package54, in conjunction
104P. A. Kolman et al. “Antechamber, an Accessory Software Package for Molecular Mechanical
Calculations”, manuscript in preparation
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with the GAFF force field105. The AM1-BCC106 procedure was employed for
generating atomic charges. This model marries complementary features of already
existing and readily available methods, namely AM1 atomic charges, the BCI
approach107, and ESPmethodologies108. AM1 atomic charges are population
quantities based directly on the occupancies of the atomic orbitals. They are not
meant to reproduce the ESP or even the multipole moments of the subject molecule,
and therefore they perform poorly in condensed-phase simulations if compared to
ESP-derived charges108. On the other hand, they can be calculated very quickly and
they capture underlying features of the electron distribution of a molecule, including
net charge and π-delocalization. Bond charge corrections (BCCs), which have been
parameterized using standard least-squares fitting procedures109 to reproduce the
HF/6-31G ESP of a training set of molecules, are then added in order to emulate the
HF/6-31G ESP. The parameterization algorithm used here is formally identical to
that developed by Bush et al. in the consensus fitting of BCIs to HF/6-31G ESPs110.
The AM1-BCC model uses few atom types because it takes advantage of the AM1
atomic charges to express subtle chemical variations of electron distribution, thus
reducing the degrees of freedom in the parameterization obtaining a great numerical
stability. The philosophy adopted is correcting semiempirical charges to reproduce
desired properties. Charge is partitioned across bonds to correct for deficiencies
encountered in the simple atomic population charges derived from the AM1 wave
function. AM1-BCC uses a simple formal bond order derived from the bond
topology of the molecule. In AM1-BCC, fitting directly to the short-range sampling
of the ESP captures features of higher order electric multipoles important to
characterize shortrange strong hydrogen bonding. Fitting directly to the HF/6-31G
ESP as in AM1-BCC uses much more information per molecule, as well as
embedding the necessary overpolarization of the ab initio wave function. This also
allows the bond charge corrections the opportunity to make up for any systematic
intrinsic deficiency in the semiempirical wave function compared to the ab initio 6-
31G wave function. The AM1-BCC method thus combines the speed of a
105P.A. Kollman et al. “Development of General AMBER Force Field (GAFF)”, manuscript in
preparation
106A. Jayaram, B.L. Bush, D.B. Jack and C.I. Bayly, J. Comput. Chem., 2000, 21, 132-146
107T. A. Halgren, J. Comput. Chem., 1996, 17, 616
108U.C. Singh and P. A. Kollman, J. Comput. Chem., 1984, 5, 129
109B.H. Besler, K.M. Merz and P. A. Kollman, J. Comput. Chem., 1990, 11, 431
110B. L. Bush, C. I. Bayly and T. A. Halgren, J. Comput. Chem, 1999, 20, 1495
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semiempirical calculation with the efficiency of the BCI approach, aiming to
achieve the quality of HF/6-31G ESP-fit charges. 
The SU5402 ligand file parametrized in this manner was manually docked to
VEGFRK keeping the same orientation described by Hubbard for FGFR1, and the
complex was minimized with the program Sander included in the Amber7 package
using parm99 force field111. The minimized structure was then submitted to a short
molecular dynamics run (100 ps). The generalized Born solvation model112 was used
in order to consider the solvent contributions. Authors report that this model could
be less accurate if compared to explicit solvent boxes, but can achieve some
advantages: it generally speed-up the simulation, certain processes may occur more
quickly probably due to the lack of solvent frictional forces, and generalized Born
simulations are also independent of the shape of the system and could thus be used
to study various conformations of a molecule that cannot otherwise be addressed by
explicit solvent simulations. An additional advantage of continuum models lies in
the implicit averaging over the solvent degrees of freedom, so that this averaging
does not need to be done by sampling the solute configurations explicitly. This
greatly simplifies calculations of thermodynamic parameters, and can be used to
examine free energy differences between different conformations of a molecule, or
to obtain binding free energies. 
The final conformation obtained was then minimized again to a rmsd of 0.15. 
Figure 14 depict resulted binding mode for SU5402 to VEGFR2K.
111P. A.Kollman et al., J. Comput. Chem., 2000, 21, 1049-1074
112V. Tsui and D. A. Case, Biopolymers (Nucl. Acid. Sci.), 2001, 56, 275-291
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Figure 14: Proposed binding mode for SU5402 to the active site of VEGFR2K
Main interactions found resemble closely those described by Hubbard for FGFR1.
In fact VEGFR2K presents a glutammic acid residue (Glu917) in the same position
as found in FGFR1K (Glu562) forming an H-bond with SU5402. A similar H-bond
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is present between the oxindole N-H and Glu917; alanine 564 of FGFR1K is
replaced by a cysteine in VEGFR2K (Cys919) wich likewise forms an H-bond
between the N-H and the oxindole carbonyl and another H-bond between the amidic
carbonyl and pyrrole N-H Finally, VEGFR2K present an asparagine residue in the
same position as found in FGFR1K and as expected an H-bond is formed between
the sidechain NH2 and the ethylcarboxyl moiety of SU5402. Another H-bound not
reported for FGFR1K seems to be formed between the ethylcarboxyl moiety of
SU5402 and Arginine 1051 present in the activation loop of VEGFR2K, but such
bond seems to be due to the particular conformation assumed by the activation loop
in our model. At the same position of Arginine 1051 FGFR1K has a lysine residue.
Those observations allowed us to choose SU5402 as reference inhibitor for docking
of 2-pyridineacetamides to VEGFR2K.
Receptor was prepared as usual from the PDB file 1VR2; hydrogens were added to
the receptor using Leap, included in the Amber7 package. The backbone was
restrained in order to keep the original conformation, expecially in the active site
position. Structure minimization was then performed to a r.m.s.d. of 0.15 using the
Generalized Born solvation model as implemented in the program Sander from
AMBER package using the Amber99 force field. Resulted geometry was than
processed with the program AutoDock Tools in order to merge non-polar
hydrogens, add solvation parameters and generate pdbqs file requested by
AutoDock3. Results are collected in Table 3 and represented graphically in Graph3.
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Table 3: Docking of 2-Pyridinacetamides to VEGFR2K; energy results and scoring
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Ki x10e6 Dock. Eg Mol/clust clust/rank
CA62 0.22 18.72 7 1
SU5402 0.56 -10.23 40 1
CA32 fII 1.08 -12.16 7 1
CA62 NH 1.86 -10.16 16 3
CA1g NO 2.4 -10.29 24 3
CA23 f 7.63 -10.76 12 1
CA16 8.91 -10.8 10 1
CA32 f 9.34 -10.74 13 1
CA55 11.8 -9.37 22 4
CA17 17.2 -10.4 23 1
CA1g d 20 -10.08 20 1
CA37 c 28 -10.17 8 9
DC65II 30.7 -10.04 13 4
CA60 32.8 0.46 4 4
CA1g MP 37.2 -9.74 12 1
CA57 38 -9.91 7 1
KL19 40.3 -9.92 9 6
KL15 40.3 -9.92 13 7
CA2 g 40.4 -9.9 9 8
DC48II 42.9 -9.83 16 3
CA50c T 64.5 -9.56 5 10
CA54 66.6 -9.54 11 2
CA58 75.1 -9.17 17 6
CA53 T 96.3 -8.92 8 6
CA5 c 122 -8.74 13 2
Graph 3: Docking of 2-Pyridinacetamides to VEGFR2K; energy results and
scoring
Observing results represented in the above Table and Graph 3 it's pretty evident that
2-pyridineacetamides does not dock properly to the VEGFR2K active site. In fact
compound CA62 wich is scored as first on the basis of predicted Ki (0.22 x 10-6) is
the worst considering docking energy (18.72 Kcal/mol), a value that suggest that the
interaction is totally unfavored. Compounds CA32 fII, CA62 NH and CA1g NO are
scored properly, but the number of conformations per cluster is pretty low and we
were not able to describe a common binding mode after visual inspection of results.
However SU5402 is predicted to be from 10 to 1000 fold more potent than our 2-
pyridine acetamides, suggesting that the pharmacological activity of the latter could
be due only in minimal part to VEGFR2K inhibition.
99
CA62
SU5402
CA32 fII
ca62 NH
CA1g NO
CA23 f
CA16
CA32 f
CA55
CA17
CA1g d
CA37 c
DC65II
CA60
CA1g M
P
CA57
KL19
KL15
CA2 g
DC48II
CA50c T
CA54
CA58
CA53 T
-20
-10
0
10
20
30
40
50
60
70
80
90
100
Ki x10e6
Dock. Eg
Docking of 2-Pyridineacetamides to FGFRK
FGFRK cristal structures bound to inhibitors SU5402 and SU4984 has been
resolved by Hubbard103 and deposed at the Protein Data Bank respectively as 1FGI
and 1AGW. SU5402 and SU4984 are represented in Figure 15 and present a
pharmacophore moiety based on a 2-indolinone nucleus.
Figure 15
Authors report that
autophosphorylation of FGFR1
induced by FGF was inhibited
by the two compounds with
IC50s of 20 to 40 µM for
SU4984 and 10 to 20 µM for
SU5402. These two
compounds also inhibited
(with similar IC50s) FGF-
induced tyrosine
phosphorylation of a 90-kD
phosphoprotein (pp90) and
mitogen-activated protein
(MAP) kinases (ERK1 and
ERK2), two intracellular
events that are dependent on
the kinase activity of FGFR1.
Both compounds also inhibited [3H]thymidine incorporation in response to FGF
stimulation113. In similar experiments, SU4984 inhibited tyrosine phosphorylation of
the platelet- derived growth factor (PDGF) receptor and of the insulin receptor114. In
contrast, SU5402 did not inhibit tyrosine phosphorylation of the insulin receptor
and was only a weak inhibitor of phosphorylation of the PDGF receptor. Neither
compound inhibited the kinase activity of the epidermal growth factor (EGF)
receptor, even at an inhibitor concentration of 200 mM. 
113M. Mohammadi et al., Mol. Cell. Biol., 1996, 16, 977.
114S.J. Isakoff et al., J. Biol. Chem., 1996, 271, 3959.
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Authors descibe accurately the binding mode for both inhibitors and a schematic
representation is depicted in Figure 16. A represent the observed binding mode for
SU4984 while B represent SU5402 bound to the active site.
Figure 16
The inhibitors bind to FGFR1K in the same general region as ATP. The oxindole of
the inhibitors occupies the same site as the ATP adenine, although the orientations
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of the bicyclic ring systems differ by nearly 180°. The chemical groups attached to
C-3 of the oxindole emerge from the cleft at approximately right angles to the
direction taken by the rest of the ATP molecule. Neither inhibitor binds near the
putative substrate peptide binding site in the COOH-terminal lobe of the kinase,
indicating that these inhibitors do not compete with substrate peptide. The oxindole
makes two hydrogen bonds to the protein backbone of FGFR1K: between N-1 of
the oxindole and the carbonyl oxygen of Glu562, and between O-2 of the oxindole
and the amide nitrogen of Ala564. Glu562 and Ala564 reside in the hinge region,
the segment between β5 and αD (residues 563 through 568) that connects the two
lobes of FGFR1K. These same two backbone groups of FGFR1K make hydrogen
bonds to N-1 and N-6 of the ATP adenine102. Figure 17 shows superpositions of
SU4984 (C) and SU5402 (D) with ATP.
Figure 17
The cavity in which the oxindole (or adenine) binds is lined with numerous
hydrophobic residues including Val492, Ala512, Ile545, Val561, Ala564, and
Leu630. In addition, Leu484 and Tyr563 provide a hydrophobic environment for
the ring proximal to the oxindole a phenyl in SU4984 and a pyrrole in SU5402. The
remainder of the interactions between the two inhibitors and FGFR1K differ. The
phenyl ring of SU4984 makes an oxygen-aromatic contact with the carbonyl oxygen
of Ala564. The piperazine ring of SU4984 is in van der Waals contact with Gly567,
a highly conserved residue in protein kinases. The terminal formyl group of SU4984
seems to be not important for inhibition, as authors state that a compound lacking
the formyl group is as potent as SU4984. In the FGFR1K-SU5402 structure, N-19
of the pyrrole ring makes an intramolecular hydrogen bond with O-2 of the
oxindole. The methyl group of the pyrrole ring is in van der Waals contact with
Gly567, and the carboxyethyl group attached to C-3' of the pyrrole ring is
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hydrogen-bonded to the side chain of Asn568, the last residue in the hinge region.
The interactions between SU4984 and FGFR1K observed in the crystal structure
would not appear to confer specificity: hydrogen bonds are made to backbone
groups, and many of the hydrophobic interactions are with conserved residues in the
PTK family. Consistent with the structural results, SU4984 exhibited rather broad
specificity. In contrast, SU5402 showed specificity for FGFR1. The hydrogen bond
between the side chain amide of Asn568 in the hinge region and the carboxyethyl
group of SU5402, and the conformational change in the nucleotide-binding loop
stabilized by such interaction confer this specificity. However, as stated above, the
vascular endothelial growth factor (VEGF) receptor has an asparagine at this
position and SU5402 is a potent inhibitor of VEGFR.
Due to it's quite absolute specificity for FGFR1K and to the major potency if
compared with other inhibitors SU5402 was choosen as reference compound for
docking of 2-pyridinacetamides to FGFR1K, and consequently 1FGI chain A was
used as PDB receptor file. Results are then reported in Table 4 and Graph 4.
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Table 4: Docking of 2-Pyridinacetamides to the FGFRK active site:
               energy results and scoring
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Ki x10e6 Dock. Eg Mol/clust clust/rank
SU5402 0.03 -12.04 39 1
CA62 0.03 -13.61 5 3
CA32 fII 0.05 -13.6 8 12
CA1g NO 0.07 -11.81 19 1
CA62 NH 0.07 -11.41 13 11
CA50c T 0.24 -12.42 5 1
CA55 0.42 -10.85 8 4
CA37 c 0.44 -12.05 19 4
DC65II 0.72 -11.68 11 7
CA16 0.72 -11.81 14 10
CA32 f 0.74 -11.74 15 10
CA54 0.84 -11.47 11 1
CA23f 0.91 -11.64 10 10
CA1g d 0.95 -11.75 23 3
CA17 1.16 -11.71 20 4
CA53 T 1.4 -11.16 11 4
KL19 1.51 -11.28 16 8
DC48II 1.69 -11.17 14 10
CA60 1.7 -0.77 11 15
CA1g MP 1.75 -11.41 21 4
CA5 c 2.47 -10.89 9 3
CA2 g 2.55 -11.29 20 7
KL15 2.65 -11.31 16 8
CA58 3.43 -10.47 11 9
CA57 4.92 -10.95 13 10
Graph 4: Docking of 2-Pyridinacetamides to the EGFRK active site:
               energy results and scoring
Observing results represented in the above Table 4 and Graph 4, as expected, it's we
can state that 2-pyridineacetamides does not dock properly to the FGFR1K active
site, behaving quite similar as in the VEGFR2K case. In fact compound CA62 is
still scored well on the basis of predicted Ki (0.03 x 10-6) and in this case also
considering docking energy (-13.61 Kcal/mol). Compound CA32FII is scored even
better by docking energy (-13.66 Kcal/mol) and shows a predicted Ki of 0.05 x 10-6.
Even other 2-pyridinacetamides present correct values of predicted Ki and docking
energy, however they show particularly low values of Molecules/Cluster and most
significative cluster ranking. Furthermore a visual inspection of results with
Autodock Tools revealed that all 2-pyridineacetamides does not dock inside the
FGFR1K active site, but tend to bind to the activation loop portion, except for
CA62 wich superpose the N-benzylpiperazino moyety with the oxindole ring of
SU5402 and seems to form an H-bond of about 2.34 Å with Alanine 564.
However, results obtained by docking of 2-pyridineacetamides to FGFR1K (1FGI)
suggest that FGFR1K inhibition give probably just a small contribution to the
overall pharmacological activity of our compounds.
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3. Experimental
Preparation of receptor's files:
When available, crystal structures have been used for docking, otherwise homology
models have been generated.
Crystal structures of EGFRK (PDB code 1M17), VEGFRK (PDB code 1VR2) and
FGFRK (PDB code 1FGI) where downloaded from the Protein Data Bank60. If
multiple files where available, it has been chosen the one with the best
crystallographic resolution. A careful analysis of the PDB files is necessary in order
to evidence eventual errors, missing aminoacids or mutated residues. Ligands were
removed from the file and if dimers were present only one chain was considered.
All waters present in the file were controlled, evaluating their position and any
eventual interaction with the active site aminoacids. If a critical water was found,
this was considered as a part of the active site. Two test run were than made,
including or not including water, using references compound having known binding
mode to assess the real importance of water during docking runs.
All hydrogens were added to the receptor using the program Leap, included in the
Amber754 package. Restraints (20kcal/mol) were added to the backbone in order to
keep the original conformation. Structure minimization was then performed to a
r.m.s.d. of 0.15 using the Generalized Born solvation model112 as implemented in
the program Sander from Amber7 package. parm99111 force field was used for
minimization. Amber charges were then used for all receptors during docking runs.
Resulted geometries were than processed with the program AutoDock Tools in
order to merge non-polar hydrogens, add solvation parameters and generate pdbqs
file requested by AutoDock350.
The cristal structure of PDGFRK has not been resolved yet, so the receptor was
constructed by homology modelling with the program Modeller6V261. Suitable
templates have been individuated using the routine “SEQ_SEARCH” as
implemented in Modeller6v2. PDB files 1VR2 and 1AGW chain A has been chosen
as templates for the catalytic domain, because it was our interest to study the kinase
receptor in his activated form, while the SH2 domain of c-SRC has been used as
template for the long interlobar insertion. 25 models were generated and models
were checked using program Procheck94. The best model was chosen and has been
treated like other PDB files. Since the first docking run with a known inhibitor
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provided two binding modes (reference compound 22), resulted complexes were
submitted to a 50ps molecular dynamic simulation. Parm99111 force field was used
for the protein while GAFF105 force field was used for benzoimidazole 2299. Missing
parameters were derived with the BCC106 procedure using program Antechamber104
from the Amber7 package. The final model was minimized to a r.m.s.d. of 0.15 and
used for docking.
An analogue procedure was employed for constructing the model of VEGFR2K
from template PDB files 1VR2 and 1AGW; the model has been used for description
of the binding mode of SU5402 to the active site of VEGFR2K, while 1VR2 was
used for docking purposes.
Preparation of ligand's files:
Ligands were constructed using program LinMopac from Fujitsu and minimized at
the semi empirical AM164 level of theory to a gradient norm of 0.01. Charges
derived from electrostatic potential108 were then calculated ab-initio at the RHF/6-
31G* level of theory using the program GAMESS21 following the Merz-Kollman
procedure65, where the electrostatic potential is calculated on the Conolly surface
and point charges are then fitted in order to reproduce the total charge using the
program Resp from the Amber7 package. Structures obtained were then treated with
the program Autotors implemented in AutoDock Tools package, in order to merge
non polar hydrogens and to select bonds allowed to rotate. Every selection was left
active, including amidic bonds. Ab-initio calculations and protein molecular
mechanics minimizations were performed on a HP64000 machine at CILEA24; semi
empirical calculations wer performed with the commercial package MOPAC2002
from Fujitsu on a PC-Linux workstation. File convertions between different formats
has been done using VEGA115, Babel116 or Molden117
Autodock parameters:
Grids for docking evaluation were computed using the program AutoGrid3 included
in the Autodock3 distribution. Grid center was centered on the active site and
80x80x80 grids with a spacing of 0.275 were calculated. Atomic affinity maps were
computed for all atoms potentially present in ligands, including carbon, aromatic
carbon, nitrogen, oxygen, sulfur, phosphorus, bromine, chlorine and fluorine.
115A. Pedretti, L. Villa, G. Vistoli, J. Mol. Graph., 2002, 21, 47-49 
116P. Walters and M. Stahl, http://smog.com/chem/babel
117G.Schaftenaar and J.H. Noordik, J. Comput.-Aided Mol. Design, 2000, 14, 123-134
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Floating point electrostatic potential grid maps were also computed, and a distance
dependent dielectric constant was chosen.
Autodock3 parameters were set in order to obtain greater accuracy. Hybrid GA-LS
Lamarckian genetic algorithm was chosen and following parameters were
modifiedfrom defaults: population size was set to 100 (ga_pop_size 100), 2.5x106
energy evaluations were requested (ga_num_evals 2500000) and 50 trials per run
were set (ga_run 50). Pseudo-Solis & Wets parameters were used for local search
and 300 iterations of Solis & Wets local search were imposed (sw_max_its 300).
Other parameters were used as default for AutoDock Tools. 
Both Autogrid and Autodock computations were performed on a HP64000 machine
at CILEA.24.
Analysis of results and visual inspection of docked conformation were performed
with AutoDock Tools or with the program VMD118 on a PC-Linux workstation.
118W. Humphrey, A. Dalke and K. Schulten, J. Molec. Graphics, 1996, 14, 33-38
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Chapter 4
Conclusions
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Conclusions
On the basis of results obtained by this research project we can conclude that:
1. The reactivity of amidino derivatives of the triacetc lactone has been thoroughly
explored, leading to the design, realization and validation of a new synthetic path
for the preparation of pyridine amido derivatives. The key step is the selective
nucleophilic attack at the C-2 position of the amidino-pyrone leading to ring
opening followed by a rearrangement controlled by the amidinic carbanion to
afford 2-pyridineacetamides. The reaction is economic and widely applicable as
demonstrated by the large number of derivatives prepared, generally with good
yields. Quantum mechanical calculation based on the evaluation of the
electrostatic potential of the amidino-pyrone reactant confirmed the observed
synthetic behavior.
The general formula of 2-pyridineacetamides synthesized is represented below
2. Results from a pharmacological screening conducted on 2-pyridine acetamides
synthesized inside this project revealed an inhibitory activity toword
proliferation of rat's aorta smooth muscular cells. The response to the drug seems
to be higher if cellular proliferation is induced by growth factors, in particular
EGF and PDGF. All active compounds are able to raise the SMC's doubling time
and to inhibit the incorporation of [3H] tymidine, confirming that the
pharmacological effect is due to reduced DNA synthesis and not to cell death.
Time course experiments evidence that the antiproliferative effect is manifested
during the fisrt moments of the G1 phase, underlining both cyclo and phase
specificity and thus supporting an interference with biochemical paths controlled
by growht factors as EGF and PDGF.
3. Structure-activity relationships have been evaluated. Both R1 and NR2
substituents have been shown to be critical for pharmacological activity. The
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contribution to the potency by R1 and NR2 can be summarized as
R1: p-Br-Ph ≥ 2,4 diCl > p-CH3O-Ph > p-Cl-Ph > p-F-Ph > Ph 
NR2: diethylamine > morpholine > N-methylpiperazine > piperidine
The potential binding mode of 2-pyridineacetamides has been investigated and
proposed on the basis of docking and molecular modeling calculations,
suggesting that preferred targets are the tyrosine kinase receptors EGFR and
PDGFR, where our amides dock correctly in the ATP binding site. Estimated Kis
and docking energies are aligned to those for known litterature compounds.
Calculations conducted on kinases different from the above mentioned didn't
furnished acceptable results, suggesting a certain selectivity toward EGFR and
PDGFR.
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